<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VYTORIN - ezetimibe and simvastatin tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VYTORIN safely and effectively. See full prescribing information for VYTORIN.<br><br>VYTORIN® (ezetimibe/simvastatin) Tablets<br>Initial U.S. Approval: 2004</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration </p>
<p class="Highlighta">     Recommended Dosing (<a href="#i4i_section_id_b754bb6d-49da-4828-8b48-79e6138988d7">2.1</a>)                                                                                      01/2012 </p>
<p class="Highlighta">     Restricted Dosing for 10/80 mg (<a href="#i4i_section_id_fb0af304-e91a-4338-8696-4b404194eda5">2.2</a>)                                                                        06/2011 </p>
<p class="Highlighta">     Coadministration with Other Drugs (<a href="#i4i_section_id_a1c9e4f9-b5e3-4173-91b6-0370db7d9bcb">2.3</a>)                                                                10/2011 </p>
<p class="Highlighta">     Patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> (<a href="#i4i_section_id_19292e57-cc5a-45a2-88ac-37df0f9c16bd">2.4</a>)                         06/2011  </p>
<p class="Highlighta">     Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>/<span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic Kidney Disease</span> 	 (<a href="#i4i_section_id_ba42e834-7a4e-4aa6-bed7-5f0bd67b7ad4">2.6</a>)                           01/2012  </p>
<p class="Highlighta">     Chinese Patients Taking Lipid-Modifying Doses (≥1 g/day Niacin) of<br>     Niacin-Containing Products (<a href="#i4i_section_id_bb155eaa-fb54-4d41-8113-99d8097175b7">2.8</a>)                                                                              06/2011 </p>
<p class="Highlighta">Contraindications (<a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">4</a>)                                                                                                       02/2012 </p>
<p class="Highlighta">Warnings and Precautions </p>
<p class="Highlighta">     <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> (<a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">5.1</a>)                                                                              02/2012 </p>
<p class="Highlighta">     Liver Enzymes (<a href="#i4i_section_id_3a5570a3-3e19-49a8-be68-29643102eaa6">5.2</a>)                                                                                                      01/2012 </p>
<p class="Highlighta">     Endocrine Function (<a href="#S5.4">5.4</a>)                                                                                                      10/2011 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">VYTORIN, which contains a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: </p>
<ul>
<li>reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. (<a href="#i4i_section_id_616d3a36-6e54-4112-ac66-63ca46fa05ac">1.1</a>)</li>
<li>reduce elevated total-C and LDL-C in patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> (HoFH), as an adjunct to other lipid-lowering treatments. (<a href="#i4i_section_id_6f4f3304-5c37-4fa0-ae20-d3794b03fbff">1.2</a>)</li>
</ul>
<p class="Highlighta">Limitations of Use (<a href="#i4i_section_id_5516f506-28d9-40b3-a034-bf00fc0183f5">1.3</a>) </p>
<ul>
<li>No incremental benefit of VYTORIN on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established.</li>
<li>VYTORIN has not been studied in Fredrickson Type I, III, IV, and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Dose range is 10/10 mg/day to 10/40 mg/day. (<a href="#i4i_section_id_b754bb6d-49da-4828-8b48-79e6138988d7">2.1</a>)</li>
<li>Recommended usual starting dose is 10/10 or 10/20 mg/day. (<a href="#i4i_section_id_b754bb6d-49da-4828-8b48-79e6138988d7">2.1</a>) </li>
<li>Due to the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, use of the 10/80-mg dose of VYTORIN should be restricted to patients who have been taking VYTORIN 10/80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity. (<a href="#i4i_section_id_fb0af304-e91a-4338-8696-4b404194eda5">2.2</a>)</li>
<li>Patients who are currently tolerating the 10/80-mg dose of VYTORIN who need to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin should be switched to an alternative statin or statin-based regimen with less potential for the drug-drug interaction. (<a href="#i4i_section_id_fb0af304-e91a-4338-8696-4b404194eda5">2.2</a>) </li>
<li>Due to the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, associated with the 10/80-mg dose of VYTORIN, patients unable to achieve their LDL-C goal utilizing the 10/40-mg dose of VYTORIN should not be titrated to the 10/80-mg dose, but should be placed on alternative LDL-C-lowering treatment(s) that provides greater LDL-C lowering. (<a href="#i4i_section_id_fb0af304-e91a-4338-8696-4b404194eda5">2.2</a>) </li>
<li>Dosing of VYTORIN should occur either ≥2 hours before or ≥4 hours after administration of a bile acid sequestrant. (<a href="#i4i_section_id_a1c9e4f9-b5e3-4173-91b6-0370db7d9bcb">2.3</a>, <a href="#i4i_section_id_238bab8a-0944-4c31-ac68-9d1f94435eb1">7.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Tablets (ezetimibe mg/simvastatin mg): 10/10, 10/20, 10/40, 10/80 (<a href="#i4i_dosage_form_strength_id_480d358d-a471-4abe-84de-4dae51bf7e1b">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Concomitant administration of strong CYP3A4 inhibitors. (<a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">4</a>, <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">5.1</a>)</li>
<li>Concomitant administration of gemfibrozil, cyclosporine, or danazol. (<a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">4</a>, <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication (<a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">4</a>, <a href="#i4i_section_id_1c527351-2dfe-4228-b5f7-e6f2f9e4b679">6.2</a>)</li>
<li>Active liver disease or unexplained persistent elevations of hepatic transaminase levels (<a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">4</a>, <a href="#i4i_section_id_3a5570a3-3e19-49a8-be68-29643102eaa6">5.2</a>)</li>
<li>Women who are pregnant or may become pregnant (<a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">4</a>, <a href="#i4i_pregnancy_id_7c78169f-43c6-4f7e-bc3a-3dcaace0cbd5">8.1</a>)</li>
<li>Nursing mothers (<a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">4</a>, <a href="#i4i_nursing_mothers_id_6555fe61-0ab5-43c8-adbd-6db10354cea8">8.3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="Bold">Patients should be advised of the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, with the 10/80-mg dose. (<a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">5.1</a>)</span></li>
<li>Patients should be advised to report promptly any symptoms of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. VYTORIN should be discontinued immediately if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. (<a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">5.1</a>)</li>
<li>Skeletal muscle effects (e.g., <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>): Risks increase with higher doses and concomitant use of certain medicines. Predisposing factors include advanced age (≥65), female gender, uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">4</a>, <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">5.1</a>, <a href="#i4i_geriatric_use_id_f55f72c8-ecdc-495f-9d69-9142919d7a3d">8.5</a>, <a href="#i4i_section_id_6ee34fef-141f-47c8-99ee-9123af5300be">8.6</a>)</li>
<li>Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter. (<a href="#i4i_section_id_3a5570a3-3e19-49a8-be68-29643102eaa6">5.2</a>)</li>
<li>VYTORIN is not recommended in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#i4i_section_id_c977d455-ba3e-4b30-bda5-f69bf9045dff">5.3</a>, <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>Common (incidence ≥2% and greater than placebo) adverse reactions in clinical trials: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, increased ALT, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (<a href="#i4i_section_id_1e28cf48-42d8-4980-9619-ee5394d254c3">6.1</a>)</li></ul>
<p class="Highlighta"><span class="Bold"><br>To report SUSPECTED ADVERSE REACTIONS, contact MSP Distribution Services (C) LLC, a subsidiary of Merck &amp; Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<a name="id_feb9e690-ce6f-4d6d-9415-03a62d69523e"></a><table>
<caption><span>Drug Interactions Associated with Increased Risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> (<a href="#i4i_section_id_a1c9e4f9-b5e3-4173-91b6-0370db7d9bcb">2.3</a>, <a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">4</a>, <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">5.1</a>, <a href="#i4i_section_id_90ff3ed0-93a0-49b1-b897-047f7abac066">7.1</a>, <a href="#i4i_section_id_8b188c52-379f-4118-b795-6a37616e9061">7.2</a>, <a href="#i4i_section_id_da292296-16ef-4389-837e-7b85a6b254a5">7.3</a>, <a href="#i4i_section_id_33a2ba71-0380-456e-ba3f-a970c3428d67">7.6</a>, <a href="#i4i_section_id_f3821fd4-53bb-485e-b0ef-ee7f1f5bd0d3">7.8</a>, <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">12.3</a>)</span></caption>
<col width="50.0%">
<col width="50.0%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="top"><span class="Bold">Interacting Agents</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">Prescribing Recommendations</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Strong CYP3A4 Inhibitors, (e.g., itraconazole, ketoconazole,<br> posaconazole, erythromycin,<br> clarithromycin, telithromycin,<br> HIV protease inhibitors, boceprevir, telaprevir, nefazodone), gemfibrozil, cyclosporine, danazol</td>
<td class="Botrule" align="left" valign="top">Contraindicated with VYTORIN</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Verapamil, diltiazem</td>
<td class="Botrule" align="left" valign="top">Do not exceed 10/10 mg VYTORIN daily</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Amiodarone, amlodipine, ranolazine</td>
<td class="Botrule" align="left" valign="top">Do not exceed 10/20 mg VYTORIN daily</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Grapefruit juice</td>
<td class="Botrule" align="left" valign="top">Avoid large quantities of grapefruit juice (&gt;1 quart daily)</td>
</tr>
</tbody>
</table>
<ul>
<li>Coumarin anticoagulants: simvastatin prolongs INR. Achieve stable INR prior to starting VYTORIN. Monitor INR frequently until stable upon initiation or alteration of VYTORIN therapy. (<a href="#i4i_section_id_f3821fd4-53bb-485e-b0ef-ee7f1f5bd0d3">7.8</a>)</li>
<li>Cholestyramine: Combination decreases exposure of ezetimibe. (<a href="#i4i_section_id_a1c9e4f9-b5e3-4173-91b6-0370db7d9bcb">2.3</a>, <a href="#i4i_section_id_238bab8a-0944-4c31-ac68-9d1f94435eb1">7.5</a>)</li>
<li>Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with VYTORIN. (<a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">5.1</a>, <a href="#i4i_section_id_8b188c52-379f-4118-b795-6a37616e9061">7.2</a>, <a href="#i4i_section_id_adb3ec13-e9cf-4652-8a54-0799f31803db">7.4</a>).</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Doses exceeding 10/20 mg/day should be used with caution and close monitoring (<a href="#i4i_section_id_ba42e834-7a4e-4aa6-bed7-5f0bd67b7ad4">2.6</a>, <a href="#i4i_section_id_6ee34fef-141f-47c8-99ee-9123af5300be">8.6</a>).</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> (HoFH)</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Restricted Dosing for 10/80 mg</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Coadministration with Other Drugs</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>/<span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic Kidney Disease</span></a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Geriatric Patients</a></h2>
<h2><a href="#section-2.8" class="toc">2.8 Chinese Patients Taking Lipid-Modifying Doses (≥1 g/day Niacin) of Niacin-Containing Products</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Liver Enzymes</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Endocrine Function</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Strong CYP3A4 Inhibitors, cyclosporine, or danazol</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Lipid-Lowering Drugs That Can Cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> When Given Alone</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Niacin</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Cholestyramine</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Digoxin</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Fibrates</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Coumarin Anticoagulants</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Colchicine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> (HoFH)</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic Kidney Disease</span> (CKD)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span></a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Liver Enzymes</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Pregnancy</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Breast-feeding</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_ee22966d-8b3a-41da-ac04-8606023ab8bd"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and other nonpharmacologic measures alone has been inadequate.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_616d3a36-6e54-4112-ac66-63ca46fa05ac"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></h2>
<p class="First">VYTORIN<span class="Sup">®</span> is indicated for the reduction of elevated total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (total-C), low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (Apo B), triglycerides (TG), and non-high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (non-HDL-C), and to increase high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL-C) in patients with primary (heterozygous familial and non-familial) <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6f4f3304-5c37-4fa0-ae20-d3794b03fbff"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> (HoFH)</h2>
<p class="First">VYTORIN is indicated for the reduction of elevated total-C and LDL-C in patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span>, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5516f506-28d9-40b3-a034-bf00fc0183f5"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Limitations of Use</h2>
<p class="First">No incremental benefit of VYTORIN on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established.</p>
<p>VYTORIN has not been studied in Fredrickson type I, III, IV, and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_e0529b26-fd60-4a87-a69b-6b9ea6880ee2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b754bb6d-49da-4828-8b48-79e6138988d7"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The usual dosage range is 10/10 mg/day to 10/40 mg/day. The recommended usual starting dose is 10/10 mg/day or 10/20 mg/day. VYTORIN should be taken as a single daily dose in the evening, with or without food. Patients who require a larger reduction in LDL-C (greater than 55%) may be started at 10/40 mg/day in the absence of moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (estimated glomerular filtration rate &lt;60 mL/min/1.73 m<span class="Sup">2</span>). After initiation or titration of VYTORIN, lipid levels may be analyzed after 2 or more weeks and dosage adjusted, if needed.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fb0af304-e91a-4338-8696-4b404194eda5"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Restricted Dosing for 10/80 mg</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Due to the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, particularly during the first year of treatment, use of the 10/80-mg dose of VYTORIN should be restricted to patients who have been taking VYTORIN 10/80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>]</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients who are currently tolerating the 10/80-mg dose of VYTORIN who need to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin should be switched to an alternative statin or statin-based regimen with less potential for the drug-drug interaction.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Due to the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, associated with the 10/80-mg dose of VYTORIN, patients unable to achieve their LDL-C goal utilizing the 10/40-mg dose of VYTORIN should not be titrated to the 10/80-mg dose, but should be placed on alternative LDL-C-lowering treatment(s) that provides greater LDL-C lowering.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a1c9e4f9-b5e3-4173-91b6-0370db7d9bcb"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Coadministration with Other Drugs</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Patients taking Verapamil  or Diltiazem</span></span></p>
<ul><li style="border-left:1px solid;"><span class="XmChange">The dose of VYTORIN should not exceed 10/10 mg/day <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>, <a href="#i4i_section_id_da292296-16ef-4389-837e-7b85a6b254a5">Drug Interactions (7.3)</a>, and <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>].</span></span></li></ul>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Patients taking Amiodarone, Amlodipine or Ranolazine</span></span></p>
<ul><li style="border-left:1px solid;"><span class="XmChange">The dose of VYTORIN should not exceed 10/20 mg/day <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>, <a href="#i4i_section_id_da292296-16ef-4389-837e-7b85a6b254a5">Drug Interactions (7.3)</a>, and <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>].</span></span></li></ul>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Patients taking Bile Acid Sequestrants</span></span></p>
<ul><li style="border-left:1px solid;"><span class="XmChange">Dosing of VYTORIN should occur either ≥2 hours before or ≥4 hours after administration of a bile acid sequestrant <span class="Italics">[see <a href="#i4i_section_id_238bab8a-0944-4c31-ac68-9d1f94435eb1">Drug Interactions (7.5)</a>].</span></span></li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_19292e57-cc5a-45a2-88ac-37df0f9c16bd"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended dosage for patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> is VYTORIN 10/40 mg/day in the evening <span class="Italics">[see <a href="#i4i_section_id_fb0af304-e91a-4338-8696-4b404194eda5">Dosage and Administration, Restricted Dosing for 10/80 mg (2.2)</a>]</span>. VYTORIN should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5c68cb46-d7b6-4bd4-9825-73ed634866d1"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dosage adjustment is necessary in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#i4i_section_id_c977d455-ba3e-4b30-bda5-f69bf9045dff">Warnings and Precautions (5.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba42e834-7a4e-4aa6-bed7-5f0bd67b7ad4"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>/<span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic Kidney Disease</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (estimated GFR ≥60 mL/min/1.73 m<span class="Sup">2</span>), no dosage adjustment is necessary. In patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> and estimated glomerular filtration rate &lt;60 mL/min/1.73 m<span class="Sup">2</span>, the dose of VYTORIN is 10/20 mg/day in the evening. In such patients, higher doses should be used with caution and close monitoring <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>; <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8992dee6-e89b-4487-9bab-18cbd07072f1"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Geriatric Patients</h2>
<p class="First">No dosage adjustment is necessary in geriatric patients <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb155eaa-fb54-4d41-8113-99d8097175b7"></a><a name="section-2.8"></a><p></p>
<h2>2.8 Chinese Patients Taking Lipid-Modifying Doses (≥1 g/day Niacin) of Niacin-Containing Products</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Because of an increased risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> in Chinese patients taking simvastatin 40 mg coadministered with lipid-modifying doses (≥1 g/day niacin) of niacin-containing products, caution should be used when treating Chinese patients with VYTORIN doses exceeding 10/20 mg/day coadministered with lipid-modifying doses (≥1 g/day niacin) of niacin-containing products. Because the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is dose-related, Chinese patients should not receive VYTORIN 10/80 mg coadministered with lipid-modifying doses of niacin-containing products. The cause of the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is not known. It is also unknown if the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with coadministration of simvastatin with lipid-modifying doses of niacin-containing products observed in Chinese patients applies to other Asian patients. <span class="Italics">[See <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>.]</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_480d358d-a471-4abe-84de-4dae51bf7e1b"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>VYTORIN<span class="Sup">®</span> 10/10, (ezetimibe 10 mg/simvastatin 10 mg tablets) are white to off-white capsule-shaped tablets with code "311" on one side.</li>
<li>VYTORIN<span class="Sup">®</span> 10/20, (ezetimibe 10 mg/simvastatin 20 mg tablets) are white to off-white capsule-shaped tablets with code "312" on one side.</li>
<li>VYTORIN<span class="Sup">®</span> 10/40, (ezetimibe 10 mg/simvastatin 40 mg tablets) are white to off-white capsule-shaped tablets with code "313" on one side.</li>
<li>VYTORIN<span class="Sup">®</span> 10/80, (ezetimibe 10 mg/simvastatin 80 mg tablets) are white to off-white capsule-shaped tablets with code "315" on one side.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">VYTORIN is contraindicated in the following conditions:</p>
<ul>
<li style="border-left:1px solid;"><span class="XmChange">Concomitant administration of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin and nefazodone) <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>].</span></span></li>
<li style="border-left:1px solid;"><span class="XmChange">Concomitant administration of gemfibrozil, cyclosporine, or danazol <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>].</span></span></li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication <span class="Italics">[see <a href="#i4i_section_id_1c527351-2dfe-4228-b5f7-e6f2f9e4b679">Adverse Reactions (6.2)</a>].</span>
</li>
<li>Active liver disease or unexplained persistent elevations in hepatic transaminase levels <span class="Italics">[see <a href="#i4i_section_id_3a5570a3-3e19-49a8-be68-29643102eaa6">Warnings and Precautions (5.2)</a>].</span>
</li>
<li>Women who are pregnant or may become pregnant<span class="Italics">. </span>Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are essential for fetal development. Because HMG-CoA reductase inhibitors (statins), such as simvastatin, decrease <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, VYTORIN may cause fetal harm when administered to a pregnant woman. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. There are no adequate and well-controlled studies of VYTORIN use during pregnancy; however, in rare reports congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, simvastatin revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. <span class="Bold">VYTORIN should be administered to women of childbearing age only when such patients are highly unlikely to conceive.</span> If the patient becomes pregnant while taking this drug, VYTORIN should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see <a href="#i4i_pregnancy_id_7c78169f-43c6-4f7e-bc3a-3dcaace0cbd5">Use in Specific Populations (8.1)</a>].</span>
</li>
<li>Nursing mothers. It is not known whether simvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require VYTORIN treatment should not breast-feed their infants <span class="Italics">[see <a href="#i4i_nursing_mothers_id_6555fe61-0ab5-43c8-adbd-6db10354cea8">Use in Specific Populations (8.3)</a>].</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_b6252b9b-cc87-46c5-b77c-3d741d4c05e0"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Simvastatin occasionally causes <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> manifested as <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> with creatine kinase above ten times the upper limit of normal (ULN). <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> sometimes takes the form of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with or without <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, and rare fatalities have occurred. The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is increased by high levels of statin activity in plasma. Predisposing factors for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> include advanced age (≥65 years), female gender, uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, is dose related.</span> In a clinical trial database in which 41,413 patients were treated with simvastatin, 24,747 (approximately 60%) of whom were enrolled in studies with a median follow-up of at least 4 years, the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> was approximately 0.03% and 0.08% at 20 and 40 mg/day, respectively. The incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with 80 mg (0.61%) was disproportionately higher than that observed at the lower doses. In these trials, patients were carefully monitored and some interacting medicinal products were excluded.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In a clinical trial in which 12,064 patients with a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> were treated with simvastatin (mean follow-up 6.7 years), the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (defined as unexplained <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with a serum creatine kinase [CK] &gt;10 times upper limit of normal [ULN]) in patients on 80 mg/day was approximately 0.9% compared with 0.02% for patients on 20 mg/day. The incidence of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (defined as <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with a CK &gt;40 times ULN) in patients on 80 mg/day was approximately 0.4% compared with 0% for patients on 20 mg/day. The incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, was highest during the first year and then notably decreased during the subsequent years of treatment. In this trial, patients were carefully monitored and some interacting medicinal products were excluded.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, is greater in patients on simvastatin 80 mg compared with other statin therapies with similar or greater LDL-C-lowering efficacy and compared with lower doses of simvastatin. Therefore, the 10/80-mg dose of VYTORIN should be used only in patients who have been taking VYTORIN 10/80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity <span class="Italics">[see <a href="#i4i_section_id_fb0af304-e91a-4338-8696-4b404194eda5">Dosage and Administration, Restricted Dosing for 10/80 mg (2.2)</a>]. </span>If, however, a patient who is currently tolerating the 10/80-mg dose of VYTORIN needs to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin, that patient should be switched to an alternative statin or statin-based regimen with less potential for the drug-drug interaction. Patients should be advised of the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. If symptoms occur, treatment should be discontinued immediately <span class="Italics">[see <a href="#i4i_section_id_3a5570a3-3e19-49a8-be68-29643102eaa6">Warnings and Precautions (5.2)</a>].</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">In the Study of Heart and Renal Protection (SHARP)<span class="Italics">,</span> 9270 patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> were allocated to receive VYTORIN 10/20 mg daily (n=4650) or placebo (n=4620). During a median follow-up period of 4.9 years, the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (defined as unexplained <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with a serum creatine kinase [CK] &gt;10 times upper limit of normal [ULN]) was 0.2% for VYTORIN and 0.1% for placebo: the incidence of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (defined as <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with a CK &gt; 40 times ULN) was 0.09% for VYTORIN and 0.02% for placebo.</span></p>
<p>In post-marketing experience with ezetimibe, cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported. Most patients who developed <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> were taking a statin prior to initiating ezetimibe. However, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> has been reported very rarely with ezetimibe monotherapy and very rarely with the addition of ezetimibe to agents known to be associated with increased risk of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, such as fibrates.</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold">All patients starting therapy with VYTORIN or whose dose of VYTORIN is being increased should be advised of the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and told to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. VYTORIN therapy should be discontinued immediately if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected.</span> In most cases, muscle symptoms and CK increases resolved when simvastatin treatment was promptly discontinued. Periodic CK determinations may be considered in patients starting therapy with simvastatin or whose dose is being increased, but there is no assurance that such monitoring will prevent <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Many of the patients who have developed <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> on therapy with simvastatin have had complicated medical histories, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> usually as a consequence of long-standing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Such patients taking VYTORIN merit closer monitoring.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">VYTORIN therapy should be discontinued if markedly elevated CPK levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. VYTORIN therapy should also be temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, e.g., <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; major surgery; <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>.</span></p>
<p><br><span class="Italics">Drug Interactions</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased by high levels of statin activity in plasma. Simvastatin is metabolized by the cytochrome P450 isoform 3A4. Certain drugs that inhibit this metabolic pathway can raise the plasma levels of simvastatin and may increase the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. These include itraconazole, ketoconazole, and posaconazole, the macrolide antibiotics erythromycin and clarithromycin, and the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or large quantities of grapefruit juice (&gt;1 quart daily). Combination of these drugs with VYTORIN is contraindicated. If treatment with itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with VYTORIN must be suspended during the course of treatment. <span class="Italics">[See <a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4)</a> and <a href="#i4i_interactions_id_17d5727c-55f6-44ae-b147-fc817a4cbc0d">Drug Interactions (7)</a>.] In vitro </span>studies have demonstrated a potential for voriconazole to inhibit the metabolism of simvastatin. Adjustment of the VYTORIN dose may be needed to reduce the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> if voriconazole must be used concomitantly with VYTORIN. <span class="Italics">[See <a href="#i4i_section_id_90ff3ed0-93a0-49b1-b897-047f7abac066">Drug Interactions (7.1)</a>.]</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">The combined use of VYTORIN with gemfibrozil, cyclosporine, or danazol is contraindicated <span class="Italics">[see <a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4)</a> and Drug Interactions (<a href="#i4i_section_id_90ff3ed0-93a0-49b1-b897-047f7abac066">7.1</a> and <a href="#i4i_section_id_8b188c52-379f-4118-b795-6a37616e9061">7.2</a>)].</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Caution should be used when prescribing other fibrates with VYTORIN, as these agents can cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> when given alone and the risk is increased when they are co-administered <span class="Italics">[see Drug Interactions (<a href="#i4i_section_id_8b188c52-379f-4118-b795-6a37616e9061">7.2</a>, <a href="#i4i_section_id_150e4340-8761-4014-998b-3b81a5e1ff82">7.7</a>)].</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with simvastatin coadministered with colchicine, and caution should be exercised when prescribing VYTORIN with colchicine <span class="Italics">[see <a href="#i4i_section_id_272ebf43-e0c9-4b5e-a0b6-b9da2de2089a">Drug Interactions (7.9)</a>].</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">The benefits of the combined use of VYTORIN with the following drugs should be carefully weighed against the potential risks of combinations: other lipid-lowering drugs (other fibrates or ≥1 g/day of niacin), amiodarone, verapamil, diltiazem, amlodipine, or ranolazine <span class="Italics">[see </span><span class="Italics"><a href="#i4i_section_id_da292296-16ef-4389-837e-7b85a6b254a5">Drug Interactions (7.3) </a>and <a href="#id_804a3f65-679f-476b-a255-48f35117ebd9">Table 6</a> in Clinical Pharmacology (12.3)]. </span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been observed with simvastatin coadministered with lipid-modifying doses (≥1 g/day niacin) of niacin-containing products. In an ongoing, double-blind, randomized cardiovascular outcomes trial, an independent safety monitoring committee identified that the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is higher in Chinese compared with non-Chinese patients taking simvastatin 40 mg or ezetimibe/simvastatin 10/40 mg coadministered with lipid-modifying doses of a niacin-containing product. Caution should be used when treating Chinese patients with VYTORIN in doses exceeding 10/20 mg/day coadministered with lipid-modifying doses of niacin-containing products. Because the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is dose-related, Chinese patients should not receive VYTORIN 10/80 mg coadministered with lipid-modifying doses of niacin-containing products. It is unknown if the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with coadministration of simvastatin with lipid-modifying doses of niacin-containing products observed in Chinese patients applies to other Asian patients <span class="Italics">[see <a href="#i4i_section_id_adb3ec13-e9cf-4652-8a54-0799f31803db">Drug Interactions (7.4)</a>].</span></span></p>
<p>Prescribing recommendations for interacting agents are summarized in Table 1 <span class="Italics">[see also <a href="#i4i_section_id_a1c9e4f9-b5e3-4173-91b6-0370db7d9bcb">Dosage and Administration (2.3)</a>, <a href="#i4i_interactions_id_17d5727c-55f6-44ae-b147-fc817a4cbc0d">Drug Interactions (7)</a>, and <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>]</span>.</p>
<a name="id_3e37a2a3-e824-4825-89d1-b2b8fdb06f85"></a><table width="75%">
<caption><span>Table 1: Drug Interactions Associated with Increased Risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></span></caption>
<col width="45.0%">
<col width="55.0%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="top"><span class="XmChange">Interacting Agents</span></td>
<td class="Botrule" align="left" valign="top"><span class="XmChange">Prescribing Recommendations </span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"><p class="First" style="border-left:1px solid;"><span class="XmChange">Strong CYP3A4 Inhibitors, e.g.:<br>  Itraconazole<br>  Ketoconazole<br>  Posaconazole<br>  Erythromycin<br>  Clarithromycin<br>  Telithromycin<br>  HIV protease inhibitors<br>  Boceprevir<br>  Telaprevir<br>  Nefazodone<br>Gemfibrozil<br>Cyclosporine<br>Danazol</span></p></td>
<td class="Botrule" align="left" valign="top"><span class="XmChange">Contraindicated with VYTORIN</span></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="XmChange">Verapamil<br>Diltiazem </span></td>
<td class="Botrule" align="left" valign="top"><span class="XmChange">Do not exceed 10/10 mg VYTORIN daily</span></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="XmChange">Amiodarone<br>Amlodipine <br>Ranolazine</span></td>
<td class="Botrule" align="left" valign="top"><span class="XmChange">Do not exceed 10/20 mg VYTORIN daily</span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="justify" valign="top"><span class="XmChange">Grapefruit juice</span></td>
<td class="Botrule" align="justify" valign="top"><span class="XmChange">Avoid large quantities of grapefruit juice (&gt;1 quart daily)</span></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a5570a3-3e19-49a8-be68-29643102eaa6"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Liver Enzymes</h2>
<p class="First">In three placebo-controlled, 12-week trials, the incidence of consecutive elevations (≥3 X ULN) in serum transaminases was 1.7% overall for patients treated with VYTORIN and appeared to be dose-related with an incidence of 2.6% for patients treated with VYTORIN 10/80. In controlled long-term (48-week) extensions, which included both newly-treated and previously-treated patients, the incidence of consecutive elevations (≥3 X ULN) in serum transaminases was 1.8% overall and 3.6% for patients treated with VYTORIN 10/80. These elevations in transaminases were generally asymptomatic, not associated with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, and returned to baseline after discontinuation of therapy or with continued treatment.</p>
<p style="border-left:1px solid;"><span class="XmChange">In SHARP, 9270 patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> were allocated to receive VYTORIN 10/20 mg daily (n=4650), or placebo (n=4620). During a median follow-up period of 4.9 years, the incidence of consecutive elevations of transaminases (&gt;3 × ULN) was 0.7% for VYTORIN and 0.6% for placebo.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">It is recommended that liver function tests be performed before the initiation of treatment with VYTORIN, and thereafter when clinically indicated. There have been rare postmarketing reports of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking statins, including simvastatin. If serious <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with clinical symptoms and/or <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs during treatment with VYTORIN, promptly interrupt therapy. If an alternate etiology is not found do not restart VYTORIN. Note that ALT may emanate from muscle, therefore ALT rising with CK may indicate <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>].</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">VYTORIN should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. Active liver diseases or unexplained persistent transaminase elevations are contraindications to the use of VYTORIN.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c977d455-ba3e-4b30-bda5-f69bf9045dff"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, VYTORIN is not recommended in these patients. <span class="Italics">[See <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Endocrine Function</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including simvastatin.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_859e184b-494c-446e-945f-273970ea44cc"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Liver enzyme abnormalities <span class="Italics">[see <a href="#i4i_section_id_3a5570a3-3e19-49a8-be68-29643102eaa6">Warnings and Precautions (5.2)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e28cf48-42d8-4980-9619-ee5394d254c3"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><span class="Bold"><span class="Italics">VYTORIN</span></span></p>
<p>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p><br>In the VYTORIN (ezetimibe/simvastatin) placebo-controlled clinical trials database of 1420 patients (age range 20-83 years, 52% women, 87% Caucasians, 3% Blacks, 5% Hispanics, 3% Asians) with a median treatment duration of 27 weeks, 5% of patients on VYTORIN and 2.2% of patients on placebo discontinued due to adverse reactions.</p>
<p>The most common adverse reactions in the group treated with VYTORIN that led to treatment discontinuation and occurred at a rate greater than placebo were:</p>
<ul>
<li>Increased ALT (0.9%)</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> (0.6%)</li>
<li>Increased AST (0.4%)</li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> (0.4%)</li>
</ul>
<p>The most commonly reported adverse reactions (incidence ≥2% and greater than placebo) in controlled clinical trials were: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5.8%), increased ALT (3.7%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (3.6%), <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> (3.6%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.8%).</p>
<p>VYTORIN has been evaluated for safety in more than 10,189 patients in clinical trials.</p>
<p>Table 2 summarizes the frequency of clinical adverse reactions reported in ≥2% of patients treated with VYTORIN (n=1420) and at an incidence greater than placebo, regardless of causality assessment, from four placebo-controlled trials.</p>
<a name="id_060aea7c-eb12-4d92-b686-1e3414e064bf"></a><table width="726.000">
<caption><span>Table 2: Clinical Adverse Reactions Occurring in ≥2% of Patients Treated with VYTORIN and at an Incidence Greater than Placebo, Regardless of Causality</span></caption>
<col width="39.4%">
<col width="15.2%">
<col width="15.2%">
<col width="15.2%">
<col width="15.2%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="middle">Body System/Organ Class<br>Adverse Reaction </td>
<td class="Botrule" align="center" valign="bottom">Placebo<br>(%)<br>n=371</td>
<td class="Botrule" align="center" valign="bottom">Ezetimibe<br>10 mg<br>(%)<br>n=302</td>
<td class="Botrule" align="center" valign="bottom">Simvastatin<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>(%)<br>n=1234</td>
<td class="Botrule" align="center" valign="bottom">VYTORIN<a href="#footnote-1" class="Sup">*</a><br>(%)<br>n=1420</td>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>All doses.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Italics">Body as a whole – general disorders</span></td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">5.4</td>
<td align="center" valign="top">6.0</td>
<td align="center" valign="top">5.9</td>
<td align="center" valign="top">5.8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Gastrointestinal system disorders</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">2.2</td>
<td align="center" valign="top">5.0</td>
<td align="center" valign="top">3.7</td>
<td align="center" valign="top">2.8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td align="center" valign="top">0.8</td>
<td align="center" valign="top">1.0</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">2.3</td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">5.0</td>
<td align="center" valign="top">5.0</td>
<td align="center" valign="top">3.6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">2.3</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">3.6</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Botrule" align="center" valign="top">1.3</td>
<td class="Botrule" align="center" valign="top">3.0</td>
<td class="Botrule" align="center" valign="top">2.0</td>
<td class="Botrule" align="center" valign="top">2.3</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Study of Heart and Renal Protection</span></p>
<p>In SHARP<span class="Italics">,</span> 9270 patients were allocated to VYTORIN 10/20 mg daily (n=4650) or placebo (n=4620) for a median follow-up period of 4.9 years. The proportion of patients who permanently discontinued study treatment as a result of either an adverse event or abnormal safety blood result was 10.4% vs. 9.8% among patients allocated to VYTORIN and placebo, respectively. Comparing those allocated to VYTORIN vs. placebo, the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (defined as unexplained <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with a serum CK &gt;10 times ULN) was 0.2% vs. 0.1% and the incidence of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (defined as <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with a CK &gt;40 times ULN) was 0.09% vs. 0.02%, respectively. Consecutive elevations of transaminases (&gt;3 × ULN) occurred in 0.7% vs. 0.6%, respectively. Patients were asked about the occurrence of unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> at each study visit: 21.5% vs. 20.9% patients ever reported muscle symptoms in the VYTORIN and placebo groups, respectively. Cancer was diagnosed during the trial in 9.4% vs. 9.5% of patients assigned to VYTORIN and placebo, respectively.</p>
<p><span class="Italics"><span class="Bold">Ezetimibe</span></span></p>
<p>Other adverse reactions reported with ezetimibe in placebo-controlled studies, regardless of causality assessment: <span class="Italics">Musculoskeletal system disorders:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>; <span class="Italics">Body as a whole – general disorders:</span> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.</p>
<p><span class="Italics"><span class="Bold">Simvastatin</span></span></p>
<p>In a clinical trial in which 12,064 patients with a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> were treated with simvastatin (mean follow-up 6.7 years), the incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (defined as unexplained <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with a serum creatine kinase [CK] &gt;10 times upper limit of normal [ULN]) in patients on 80 mg/day was approximately 0.9% compared with 0.02% for patients on 20 mg/day. The incidence of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (defined as <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with a CK &gt;40 times ULN) in patients on 80 mg/day was approximately 0.4% compared with 0% for patients on 20 mg/day. The incidence of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, was highest during the first year and then notably decreased during the subsequent years of treatment. In this trial, patients were carefully monitored and some interacting medicinal products were excluded.</p>
<p>Other adverse reactions reported with simvastatin in placebo-controlled clinical studies, regardless of causality assessment: <span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>; <span class="Italics">Ear and labyrinth disorders:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>;<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>; <span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus; <span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>; <span class="Italics">Body as a whole – general disorders:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>; <span class="Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Bold">Laboratory Tests</span></p>
<p>Marked persistent increases of hepatic serum transaminases have been noted <span class="Italics">[see <a href="#i4i_section_id_3a5570a3-3e19-49a8-be68-29643102eaa6">Warnings and Precautions (5.2)</a>]</span>. Elevated alkaline phosphatase and γ-glutamyl transpeptidase have been reported. About 5% of patients taking simvastatin had elevations of CK levels of 3 or more times the normal value on one or more occasions. This was attributable to the noncardiac fraction of CK <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c527351-2dfe-4228-b5f7-e6f2f9e4b679"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">Because the below reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>The following adverse reactions have been reported in post-marketing experience for VYTORIN or ezetimibe or simvastatin: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>; <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; a variety of skin changes (e.g., <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, discoloration, dryness of skin/mucous membranes, changes to hair/nails); <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>; <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>; <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>]</span>; <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>/<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>; fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>; <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>; <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; elevations in liver transaminases; elevated creatine phosphokinase.</p>
<p> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been reported.</p>
<p>In addition, an apparent <span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">hypersensitivity syndrome</span> has been reported rarely that has included one or more of the following features: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, lupus erythematous-like syndrome, <span class="product-label-link" type="condition" conceptid="255348" conceptname="Polymyalgia rheumatica">polymyalgia rheumatica</span>, <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, positive ANA, ESR increase, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
<p>There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (e.g., <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_17d5727c-55f6-44ae-b147-fc817a4cbc0d"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">[See <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>.]</span></p>
<p><span class="Italics">VYTORIN</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90ff3ed0-93a0-49b1-b897-047f7abac066"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Strong CYP3A4 Inhibitors, cyclosporine, or danazol</h2>
<p class="First">Strong CYP3A4 inhibitors: The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is increased by reducing the elimination of the simvastatin component of VYTORIN. Hence when VYTORIN is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, particularly with higher doses of VYTORIN. <span class="Italics">[See <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a> and <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>.]</span> Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated <span class="Italics">[see <a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4)</a>]. </span> If treatment with itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with VYTORIN must be suspended during the course of treatment.</p>
<p>Although not studied clinically, voriconazole has been shown to inhibit lovastatin metabolism <span class="Italics">in vitro</span> (human liver microsomes). Therefore, voriconazole is likely to increase the plasma concentration of simvastatin. It is recommended that dose adjustment of VYTORIN be considered during concomitant use of voriconazole and VYTORIN to reduce the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>].</span></p>
<p>Cyclosporine or Danazol: The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased by concomitant administration of cyclosporine or danazol. Therefore, concomitant use of these drugs is contraindicated. <span class="Italics">[see <span class="Italics"><a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4)</a></span>, <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1) </a>and <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b188c52-379f-4118-b795-6a37616e9061"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Lipid-Lowering Drugs That Can Cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> When Given Alone</h2>
<p class="First">Gemfibrozil: Contraindicated with VYTORIN <span class="Italics">[see <span class="Italics"><span class="Italics"><a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4) </a></span>and </span><span class="Italics"><a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>].</span></span></p>
<p>Other fibrates: Caution should be used when prescribing with VYTORIN <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da292296-16ef-4389-837e-7b85a6b254a5"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers</h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, is increased by concomitant administration of amiodarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem or amlodipine <span class="Italics">[see <a href="#i4i_section_id_a1c9e4f9-b5e3-4173-91b6-0370db7d9bcb">Dosage and Administration (2.3)</a> and <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1) </a>and <a href="#id_804a3f65-679f-476b-a255-48f35117ebd9">Table 6</a> in Clinical Pharmacology (12.3)]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_adb3ec13-e9cf-4652-8a54-0799f31803db"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Niacin</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been observed with simvastatin coadministered with lipid-modifying doses (≥1 g/day niacin) of niacin-containing products. The benefits of the combined use of VYTORIN with niacin should be carefully weighed against the potential risks of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. In particular, caution should be used when treating Chinese patients with VYTORIN doses exceeding 10/20 mg/day coadministered with lipid-modifying doses of niacin-containing products. Because the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is dose-related, Chinese patients should not receive VYTORIN 10/80 mg coadministered with lipid-modifying doses of niacin-containing products. <span class="Italics">[See <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_238bab8a-0944-4c31-ac68-9d1f94435eb1"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Cholestyramine</h2>
<p class="First">Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. The incremental LDL-C reduction due to adding VYTORIN to cholestyramine may be reduced by this interaction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_33a2ba71-0380-456e-ba3f-a970c3428d67"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Digoxin</h2>
<p class="First">In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in plasma digoxin concentrations. Patients taking digoxin should be monitored appropriately when VYTORIN is initiated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_150e4340-8761-4014-998b-3b81a5e1ff82"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Fibrates</h2>
<p class="First">The safety and effectiveness of VYTORIN administered with fibrates have not been established. Because it is known that the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of fibrates, VYTORIN should be administered with caution when used concomitantly with fibrates (other than gemfibrozil, which is contraindicated) <span class="Italics">[see <a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4)</a> and <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>].</span></p>
<p>Fibrates may increase <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> excretion into the bile, leading to <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>. In a preclinical study in dogs, ezetimibe increased <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in the gallbladder bile <span class="Italics">[see <a href="#i4i_animal_pharmacology_id_48cdc79f-3dc3-4dcb-bccd-47a0235b2f29">Animal Toxicology and/or Pharmacology (13.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f3821fd4-53bb-485e-b0ef-ee7f1f5bd0d3"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Coumarin Anticoagulants</h2>
<p class="First">Simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in a normal volunteer study and in a hypercholesterolemic patient study, respectively. With other statins, clinically evident <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time has been reported in a few patients taking coumarin anticoagulants concomitantly. In such patients, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be determined before starting VYTORIN and frequently enough during early therapy to ensure that no significant alteration of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time occurs. Once a stable <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time has been documented, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of VYTORIN is changed or discontinued, the same procedure should be repeated. Simvastatin therapy has not been associated with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or with changes in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients not taking anticoagulants.</p>
<p>Concomitant administration of ezetimibe (10 mg once daily) had no significant effect on bioavailability of warfarin and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in a study of twelve healthy adult males. There have been post-marketing reports of increased INR in patients who had ezetimibe added to warfarin. Most of these patients were also on other medications.</p>
<p>The effect of VYTORIN on the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_272ebf43-e0c9-4b5e-a0b6-b9da2de2089a"></a><a name="section-7.9"></a><p></p>
<h2>7.9 Colchicine</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with simvastatin coadministered with colchicine, and caution should be exercised when prescribing VYTORIN with colchicine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_669afb16-0b70-49e4-9603-9ac3bf4ac066"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_7c78169f-43c6-4f7e-bc3a-3dcaace0cbd5"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category X.</span></p>
<p><span class="Italics">[See <span class="Italics"><a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4)</a></span>.]</span></p>
<p><span class="Italics">VYTORIN</span></p>
<p>VYTORIN is contraindicated in women who are or may become pregnant. Lipid-lowering drugs offer no benefit during pregnancy, because <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are needed for normal fetal development. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> therapy. There are no adequate and well-controlled studies of VYTORIN use during pregnancy; however, there are rare reports of congenital anomalies in infants exposed to statins <span class="Italics">in utero</span>. Animal reproduction studies of simvastatin in rats and rabbits showed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are essential for fetal development. Because statins, such as simvastatin, decrease <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, VYTORIN may cause fetal harm when administered to a pregnant woman. If VYTORIN is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Women of childbearing potential, who require VYTORIN treatment for a lipid disorder, should be advised to use effective contraception. For women trying to conceive, discontinuation of VYTORIN should be considered. If pregnancy occurs, VYTORIN should be immediately discontinued.</p>
<p><span class="Italics">Ezetimibe</span></p>
<p>In oral (gavage) embryo-fetal development studies of ezetimibe conducted in rats and rabbits during organogenesis, there was no evidence of embryolethal effects at the doses tested (250, 500, 1000 mg/kg/day). In rats, increased incidences of common fetal skeletal findings (extra pair of thoracic ribs, unossified cervical vertebral centra, shortened ribs) were observed at 1000 mg/kg/day (~10 times the human exposure at 10 mg daily based on AUC<span class="Sub">0-24hr</span> for total ezetimibe). In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC<span class="Sub">0-24hr</span> for total ezetimibe). Ezetimibe crossed the placenta when pregnant rats and rabbits were given multiple oral doses.</p>
<p>Multiple-dose studies of ezetimibe coadministered with statins in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. Reproductive findings occur at lower doses in coadministration therapy compared to monotherapy.</p>
<p><span class="Italics">Simvastatin</span></p>
<p>Simvastatin was not teratogenic in rats or rabbits at doses (25, 10 mg/kg/day, respectively) that resulted in 3 times the human exposure based on mg/m<span class="Sup">2</span> surface area. However, in studies with another structurally-related statin, skeletal malformations were observed in rats and mice.</p>
<p>There are rare reports of congenital anomalies following intrauterine exposure to statins. In a review of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or another structurally-related statin, the incidences of congenital anomalies, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span> and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> did not exceed what would be expected in the general population. The number of cases is adequate only to exclude a 3- to 4-fold increase in congenital anomalies over the background incidence. In 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_6555fe61-0ab5-43c8-adbd-6db10354cea8"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether simvastatin is excreted in human milk. Because a small amount of another drug in this class is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women taking simvastatin should not nurse their infants. A decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother <span class="Italics">[see <span class="Italics"><a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4)</a></span>]</span>.</p>
<p>In rat studies, exposure to ezetimibe in nursing pups was up to half of that observed in maternal plasma. It is not known whether ezetimibe or simvastatin are excreted into human breast milk. Because a small amount of another drug in the same class as simvastatin is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women who are nursing should not take VYTORIN<span class="Italics"> [see <a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_1b2530ba-6347-480a-88c3-23e5b1d3c0bc"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The effects of ezetimibe coadministered with simvastatin (n=126) compared to simvastatin monotherapy (n=122) have been evaluated in adolescent boys and girls with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (HeFH). In a multicenter, double-blind, controlled study followed by an open-label phase, 142 boys and 106 postmenarchal girls, 10 to 17 years of age (mean age 14.2 years, 43% females, 82% Caucasians, 4% Asian, 2% Blacks, 13% multiracial) with HeFH were randomized to receive either ezetimibe coadministered with simvastatin or simvastatin monotherapy. Inclusion in the study required 1) a baseline LDL-C level between 160 and 400 mg/dL and 2) a medical history and clinical presentation consistent with HeFH. The mean baseline LDL-C value was 225 mg/dL (range: 161-351 mg/dL) in the ezetimibe coadministered with simvastatin group compared to 219 mg/dL (range: 149-336 mg/dL) in the simvastatin monotherapy group. The patients received coadministered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) or simvastatin monotherapy (10 mg, 20 mg, or 40 mg) for 6 weeks, coadministered ezetimibe and 40 mg simvastatin or 40 mg simvastatin monotherapy for the next 27 weeks, and open-label coadministered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter.</p>
<p>The results of the study at Week 6 are summarized in Table 3. Results at Week 33 were consistent with those at Week 6.</p>
<a name="id_ae85b208-c7b1-464c-9acc-4e9b48bf72d4"></a><table width="751.000">
<caption><span>Table 3: Mean Percent Difference at Week 6 Between the Pooled Ezetimibe Coadministered with Simvastatin Group and the Pooled Simvastatin Monotherapy Group in Adolescent Patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span></span></caption>
<col width="25.7%">
<col width="12.0%">
<col width="14.4%">
<col width="11.2%">
<col width="12.0%">
<col width="11.2%">
<col width="13.6%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Total-C</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">LDL-C</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Non-HDL-C</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">TG
                                    </span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">HDL-C</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="center" valign="middle">Mean percent difference between treatment groups</td>
<td class="Botrule" align="center" valign="middle">-12%</td>
<td class="Botrule" align="center" valign="middle">-15%</td>
<td class="Botrule" align="center" valign="middle">-12%</td>
<td class="Botrule" align="center" valign="middle">-14%</td>
<td class="Botrule" align="center" valign="middle">-2%</td>
<td class="Botrule" align="center" valign="middle">+0.1%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle">95% Confidence Interval</td>
<td class="Botrule" align="center" valign="middle">(-15%, -9%)</td>
<td class="Botrule" align="center" valign="middle">(-18%, -12%)</td>
<td class="Botrule" align="center" valign="middle">(-15%, -9%)</td>
<td class="Botrule" align="center" valign="middle">(-17%, -11%)</td>
<td class="Botrule" align="center" valign="middle">(-9, +4)</td>
<td class="Botrule" align="center" valign="middle">(-3, +3)</td>
</tr>
</tbody>
</table>
<p>From the start of the trial to the end of Week 33, discontinuations due to an adverse reaction occurred in 7 (6%) patients in the ezetimibe coadministered with simvastatin group and in 2 (2%) patients in the simvastatin monotherapy group.</p>
<p>During the trial, hepatic transaminase elevations (two consecutive measurements for ALT and/or AST ≥3 X ULN) occurred in four (3%) individuals in the ezetimibe coadministered with simvastatin group and in two (2%) individuals in the simvastatin monotherapy group. Elevations of CPK (≥10 X ULN) occurred in two (2%) individuals in the ezetimibe coadministered with simvastatin group and in zero individuals in the simvastatin monotherapy group.</p>
<p>In this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on menstrual cycle length in girls.</p>
<p>Coadministration of ezetimibe with simvastatin at doses greater than 40 mg/day has not been studied in adolescents. Also, VYTORIN has not been studied in patients younger than 10 years of age or in pre-menarchal girls.</p>
<p><br><span class="Italics">Ezetimibe</span></p>
<p>Based on total ezetimibe (ezetimibe + ezetimibe-glucuronide) there are no pharmacokinetic differences between adolescents and adults. Pharmacokinetic data in the pediatric population &lt;10 years of age are not available.</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>The pharmacokinetics of simvastatin has not been studied in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_f55f72c8-ecdc-495f-9d69-9142919d7a3d"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 10,189 patients who received VYTORIN in clinical studies, 3242 (32%) were 65 and older (this included 844 (8%) who were 75 and older). No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients but greater sensitivity of some older individuals cannot be ruled out. Since advanced age (≥65 years) is a predisposing factor for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, VYTORIN should be prescribed with caution in the elderly. <span class="Italics">[See <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>.]</span></p>
<p>Because advanced age (≥65 years) is a predisposing factor for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, VYTORIN should be prescribed with caution in the elderly. In a clinical trial of patients treated with simvastatin 80 mg/day, patients ≥65 years of age had an increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, compared to patients &lt;65 years of age. <span class="Italics">[See <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1) </a>and <a href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">Clinical Pharmacology (12.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ee34fef-141f-47c8-99ee-9123af5300be"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In the SHARP trial of 9270 patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (6247 non-dialysis patients with median serum creatinine 2.5 mg/dL and median estimated glomerular filtration rate 25.6 mL/min/1.73 m<span class="Sup">2</span>, and 3023 dialysis patients), the incidence of serious adverse events, adverse events leading to discontinuation of study treatment, or adverse events of special interest (musculoskeletal adverse events, liver enzyme abnormalities, incident cancer) was similar between patients ever assigned to VYTORIN 10/20 mg (n=4650) or placebo (n=4620) during a median follow-up of 4.9 years. However, because <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is a risk factor for statin-associated <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, doses of VYTORIN exceeding 10/20 mg should be used with caution and close monitoring in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. <span class="Italics">[See <a href="#i4i_section_id_ba42e834-7a4e-4aa6-bed7-5f0bd67b7ad4">Dosage and Administration (2.6)</a>, <a href="#i4i_section_id_1e28cf48-42d8-4980-9619-ee5394d254c3">Adverse Reactions (6.1)</a>, and <a href="#S14.3">Clinical Studies (14.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_246aa38f-c1bf-44e9-afb6-bdd183e61e17"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">VYTORIN is contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic transaminases. VYTORIN is not recommended in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <span class="Italics">[See <span class="Italics"><a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4)</a></span> and <a href="#i4i_section_id_3a5570a3-3e19-49a8-be68-29643102eaa6">Warnings and Precautions (5.2)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_22bcd5b8-8fde-486f-baf0-e38b08a7064b"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Italics">VYTORIN</span></p>
<p>No specific treatment of overdosage with VYTORIN can be recommended. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, symptomatic and supportive measures should be employed.</p>
<p><span class="Italics">Ezetimibe</span></p>
<p>In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, or 40 mg/day to 18 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> for up to 56 days, was generally well tolerated. </p>
<p>A few cases of overdosage have been reported; most have not been associated with adverse experiences. Reported adverse experiences have not been serious. </p>
<p><span class="Italics">Simvastatin</span></p>
<p>Significant lethality was observed in mice after a single oral dose of 9 g/m<span class="Sup">2</span>. No evidence of lethality was observed in rats or dogs treated with doses of 30 and 100 g/m<span class="Sup">2</span>, respectively. No specific diagnostic signs were observed in rodents. At these doses the only signs seen in dogs were <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and mucoid stools.</p>
<p>A few cases of overdosage with simvastatin have been reported; the maximum dose taken was 3.6 g. All patients recovered without sequelae.</p>
<p>The dialyzability of simvastatin and its metabolites in man is not known at present.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_2c8ed8fb-606e-4de2-9edc-c550125bb526"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VYTORIN contains ezetimibe, a selective inhibitor of intestinal <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and related phytosterol absorption, and simvastatin, an HMG-CoA reductase inhibitor.</p>
<p>The chemical name of ezetimibe is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The empirical formula is C<span class="Sub">24</span>H<span class="Sub">21</span>F<span class="Sub">2</span>NO<span class="Sub">3</span> and its molecular weight is 409.4. </p>
<p>Ezetimibe is a white, crystalline powder that is freely to very soluble in ethanol, methanol, and acetone and practically insoluble in water. Its structural formula is:</p>
<div class="Figure"><img alt="image of ezetimibe structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2507c644-e445-4e31-8d15-82afcb15f274&amp;name=vytorin-01.jpg"></div>
<p>Simvastatin, an inactive lactone, is hydrolyzed to the corresponding β-hydroxyacid form, which is an inhibitor of HMG-CoA reductase. Simvastatin is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2<span class="Italics">H</span>-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1<span class="Italics">S</span>-[1α,3α,7β,8β(2<span class="Italics">S*</span>,4<span class="Italics">S*</span>),-8aβ]]. The empirical formula of simvastatin is C<span class="Sub">25</span>H<span class="Sub">38</span>O<span class="Sub">5</span> and its molecular weight is 418.57. </p>
<p>Simvastatin is a white to off-white, nonhygroscopic, crystalline powder that is practically insoluble in water and freely soluble in chloroform, methanol and ethanol. Its structural formula is:</p>
<div class="Figure"><img alt="image of simvastatin structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2507c644-e445-4e31-8d15-82afcb15f274&amp;name=vytorin-02.jpg"></div>
<p>VYTORIN is available for oral use as tablets containing 10 mg of ezetimibe, and 10 mg of simvastatin (VYTORIN 10/10), 20 mg of simvastatin (VYTORIN 10/20), 40 mg of simvastatin (VYTORIN 10/40), or 80 mg of simvastatin (VYTORIN 10/80). Each tablet contains the following inactive ingredients: butylated hydroxyanisole NF, citric acid monohydrate USP, croscarmellose sodium NF, hypromellose USP, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, and propyl gallate NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_55082e89-eec4-4a7b-a3e9-e1dff0777548"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_c8367eb9-2d06-4727-a6f7-40fce2151f51"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><span class="Italics">VYTORIN</span></p>
<p>Plasma <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is derived from intestinal absorption and endogenous synthesis. VYTORIN contains ezetimibe and simvastatin, two lipid-lowering compounds with complementary mechanisms of action. VYTORIN reduces elevated total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, TG, and non-HDL-C, and increases HDL-C through dual inhibition of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption and synthesis.</p>
<p><br><span class="Italics">Ezetimibe</span></p>
<p>Ezetimibe reduces blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> by inhibiting the absorption of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and phytosterols. In a 2-week clinical study in 18 hypercholesterolemic patients, ezetimibe inhibited intestinal <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption by 54%, compared with placebo. Ezetimibe had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E and did not impair adrenocortical steroid hormone production.</p>
<p>Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, leading to a decrease in the delivery of intestinal <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> to the liver. This causes a reduction of hepatic <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> stores and an increase in clearance of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> from the blood; this distinct mechanism is complementary to that of statins <span class="Italics">[see <a href="#i4i_clinical_studies_id_0602b924-dad1-4885-b8d9-561a92765138">Clinical Studies (14)</a>]</span>.</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>Simvastatin is a prodrug and is hydrolyzed to its active β-hydroxyacid form, simvastatin acid, after administration. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. In addition, simvastatin reduces very-low-density lipoproteins (VLDL) and TG and increases HDL-C.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_e089042e-1143-41e4-afbb-19c4711ab3f9"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Clinical studies have demonstrated that elevated levels of total-C, LDL-C and Apo B, the major protein constituent of LDL, promote human <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. In addition, decreased levels of HDL-C are associated with the development of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C. Like LDL, <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-enriched triglyceride-rich lipoproteins, including VLDL, intermediate-density lipoproteins (IDL), and remnants, can also promote <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. The independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The results of a bioequivalence study in healthy subjects demonstrated that the VYTORIN (ezetimibe/simvastatin) 10 mg/10 mg to 10 mg/80 mg combination tablets are bioequivalent to coadministration of corresponding doses of ezetimibe (ZETIA<span class="Sup">®</span>) and simvastatin (ZOCOR<span class="Sup">®</span>) as individual tablets.</p>
<p><span class="Italics"><span class="Bold">Absorption</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>After oral administration, ezetimibe is absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide).</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>The availability of the β-hydroxyacid to the systemic circulation following an oral dose of simvastatin was found to be less than 5% of the dose, consistent with extensive hepatic first-pass extraction.</p>
<p><span class="Italics"><span class="Bold">Effect of Food on Oral Absorption</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>Concomitant food administration (high-fat or non-fat meals) had no effect on the extent of absorption of ezetimibe when administered as 10-mg tablets. The C<span class="Sub">max</span> value of ezetimibe was increased by 38% with consumption of high-fat meals.</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>Relative to the fasting state, the plasma profiles of both active and total inhibitors of HMG-CoA reductase were not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal.</p>
<p><span class="Italics"><span class="Bold">Distribution</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>Ezetimibe and ezetimibe-glucuronide are highly bound (&gt;90%) to human plasma proteins.</p>
<p><span class="Italics">Simvastatin</span></p>
<p>Both simvastatin and its β-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins. When radiolabeled simvastatin was administered to rats, simvastatin-derived radioactivity crossed the blood-brain barrier.</p>
<p><span class="Italics"><span class="Bold">Metabolism and Excretion</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>Ezetimibe is primarily metabolized in the small intestine and liver via glucuronide conjugation with subsequent biliary and renal excretion. Minimal oxidative metabolism has been observed in all species evaluated. </p>
<p>In humans, ezetimibe is rapidly metabolized to ezetimibe-glucuronide. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10 to 20% and 80 to 90% of the total drug in plasma, respectively. Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide. Plasma concentration-time profiles exhibit multiple peaks, suggesting enterohepatic recycling. </p>
<p>Following oral administration of <span class="Sup">14</span>C-ezetimibe (20 mg) to human subjects, total ezetimibe (ezetimibe + ezetimibe-glucuronide) accounted for approximately 93% of the total radioactivity in plasma. After 48 hours, there were no detectable levels of radioactivity in the plasma.</p>
<p>Approximately 78% and 11% of the administered radioactivity were recovered in the feces and urine, respectively, over a 10-day collection period. Ezetimibe was the major component in feces and accounted for 69% of the administered dose, while ezetimibe-glucuronide was the major component in urine and accounted for 9% of the administered dose.</p>
<p><span class="Italics">Simvastatin</span></p>
<p>Simvastatin is a lactone that is readily hydrolyzed <span class="Italics">in vivo</span> to the corresponding β-hydroxyacid, a potent inhibitor of HMG-CoA reductase. Inhibition of HMG-CoA reductase is a basis for an assay in pharmacokinetic studies of the β-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin. The major active metabolites of simvastatin present in human plasma are the β-hydroxyacid of simvastatin and its 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives.</p>
<p>Following an oral dose of <span class="Sup">14</span>C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces. Plasma concentrations of total radioactivity (simvastatin plus <span class="Sup">14</span>C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose.</p>
<p><span class="Italics"><span class="Bold">Specific Populations</span></span></p>
<p><span class="Italics"><span class="Bold">Geriatric Patients</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>In a multiple-dose study with ezetimibe given 10 mg once daily for 10 days, plasma concentrations for total ezetimibe were about 2-fold higher in older (≥65 years) healthy subjects compared to younger subjects.</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.</p>
<p><span class="Italics"><span class="Bold">Pediatric Patients:</span> [See <a href="#i4i_pediatric_use_id_1b2530ba-6347-480a-88c3-23e5b1d3c0bc">Pediatric Use (8.4)</a>.]</span></p>
<p><span class="Italics"><span class="Bold">Gender</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>In a multiple-dose study with ezetimibe given 10 mg once daily for 10 days, plasma concentrations for total ezetimibe were slightly higher (&lt;20%) in women than in men.</p>
<p><span class="Italics"><span class="Bold">Race</span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>Based on a meta-analysis of multiple-dose pharmacokinetic studies, there were no pharmacokinetic differences between Black and Caucasian subjects. Studies in Asian subjects indicated that the pharmacokinetics of ezetimibe was similar to those seen in Caucasian subjects.</p>
<p><span class="Italics"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>After a single 10-mg dose of ezetimibe, the mean exposure (based on area under the curve [AUC]) to total ezetimibe was increased approximately 1.7-fold in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 6), compared to healthy subjects. The mean AUC values for total ezetimibe and ezetimibe increased approximately 3- to 4-fold and 5- to 6-fold, respectively, in patients with moderate (Child-Pugh score 7 to 9) or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 10 to 15). In a 14-day, multiple-dose study (10 mg daily) in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the mean AUC for total ezetimibe and ezetimibe increased approximately 4-fold compared to healthy subjects.</p>
<p><span class="Italics"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p><span class="Italics">Ezetimibe</span></p>
<p>After a single 10-mg dose of ezetimibe in patients with severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (n=8; mean CrCl ≤30 mL/min/1.73 m<span class="Sup">2</span>), the mean AUC for total ezetimibe and ezetimibe increased approximately 1.5-fold, compared to healthy subjects (n=9).</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>Pharmacokinetic studies with another statin having a similar principal route of elimination to that of simvastatin have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (as measured by creatinine clearance).</p>
<p><span class="Italics"><span class="Bold">Drug Interactions [See also <a href="#i4i_interactions_id_17d5727c-55f6-44ae-b147-fc817a4cbc0d">Drug Interactions (7)</a>.]</span></span></p>
<p>No clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was seen when ezetimibe was coadministered with simvastatin. No specific pharmacokinetic drug interaction studies with VYTORIN have been conducted other than the following study with NIASPAN (Niacin extended-release tablets).</p>
<p><span class="Bold">Niacin:</span> The effect of VYTORIN (10/20 mg daily for 7 days) on the pharmacokinetics of NIASPAN extended-release tablets (1000 mg for 2 days and 2000 mg for 5 days following a low-fat breakfast) was studied in healthy subjects. The mean C<span class="Sub">max</span> and AUC of niacin increased 9% and 22%, respectively. The mean C<span class="Sub">max</span> and AUC of nicotinuric acid increased 10% and 19%, respectively (N=13). In the same study, the effect of NIASPAN on the pharmacokinetics of VYTORIN was evaluated (N=15). While concomitant NIASPAN decreased the mean C<span class="Sub">max</span> of total ezetimibe (1%), and simvastatin (2%), it increased the mean C<span class="Sub">max</span> of simvastatin acid (18%). In addition, concomitant NIASPAN increased the mean AUC of total ezetimibe (26%), simvastatin (20%), and simvastatin acid (35%). </p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been observed with simvastatin coadministered with lipid-modifying doses (≥1 g/day niacin) of niacin-containing products.<span class="Italics"> [See <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a> and <a href="#i4i_section_id_adb3ec13-e9cf-4652-8a54-0799f31803db">Drug Interactions (7.4)</a>.]</span></p>
<p><span class="Bold">Cytochrome P450:</span> Ezetimibe had no significant effect on a series of probe drugs (caffeine, dextromethorphan, tolbutamide, and IV midazolam) known to be metabolized by cytochrome P450 (1A2, 2D6, 2C8/9 and 3A4) in a "cocktail" study of twelve healthy adult males. This indicates that ezetimibe is neither an inhibitor nor an inducer of these cytochrome P450 isozymes, and it is unlikely that ezetimibe will affect the metabolism of drugs that are metabolized by these enzymes.</p>
<p>In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin. This indicates that simvastatin is not an inhibitor of CYP3A4 and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.</p>
<p>Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.</p>
<p>Simvastatin is a substrate for CYP3A4. Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. <span class="Italics">[See <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>; <a href="#i4i_section_id_90ff3ed0-93a0-49b1-b897-047f7abac066">Drug Interactions (7.1)</a>.]</span></p>
<p><br><span class="Italics">Ezetimibe</span></p>
<a name="id_9b1a3fe3-9ad6-46c6-b9cb-0c385368b236"></a><table width="701.000">
<caption><span>Table 4: Effect of Coadministered Drugs on Total Ezetimibe</span></caption>
<col width="50.2%">
<col width="27.0%">
<col width="22.8%">
<thead>
<tr class="First">
<td class="Toprule" align="center" rowspan="2" valign="top"><span class="Bold">Coadministered Drug and Dosing Regimen</span></td>
<td align="center" colspan="2" valign="top"><span class="Bold">Total Ezetimibe
                                    </span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Change in AUC</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Change in C<span class="Sub">max</span></span></td>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>See 7. Drug Interactions</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Cyclosporine-stable dose required (75-150 mg BID)
                                    <span class="Sup">,</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="top">↑240%</td>
<td class="Botrule" align="center" valign="top">↑290%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Fenofibrate, 200 mg QD, 14 days<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="top">↑48%</td>
<td class="Botrule" align="center" valign="top">↑64%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Gemfibrozil, 600 mg BID, 7 days<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="top">↑64%</td>
<td class="Botrule" align="center" valign="top">↑91%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Cholestyramine, 4 g BID, 14 days<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="top">↓55%</td>
<td class="Botrule" align="center" valign="top">↓4%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Aluminum &amp; magnesium hydroxide combination antacid, single dose
                                 </td>
<td class="Botrule" align="center" valign="top">↓4%</td>
<td class="Botrule" align="center" valign="top">↓30%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Cimetidine, 400 mg BID, 7 days</td>
<td class="Botrule" align="center" valign="top">↑6%</td>
<td class="Botrule" align="center" valign="top">↑22%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Glipizide, 10 mg, single dose</td>
<td class="Botrule" align="center" valign="top">↑4%</td>
<td class="Botrule" align="center" valign="top">↓8%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Statins</span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    Lovastatin 20 mg QD, 7 days</td>
<td class="Botrule" align="center" valign="top">↑9%</td>
<td class="Botrule" align="center" valign="top">↑3%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    Pravastatin 20 mg QD, 14 days</td>
<td class="Botrule" align="center" valign="top">↑7%</td>
<td class="Botrule" align="center" valign="top">↑23%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    Atorvastatin 10 mg QD, 14 days</td>
<td class="Botrule" align="center" valign="top">↓2%</td>
<td class="Botrule" align="center" valign="top">↑12%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    Rosuvastatin 10 mg QD, 14 days</td>
<td class="Botrule" align="center" valign="top">↑13%</td>
<td class="Botrule" align="center" valign="top">↑18%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">    Fluvastatin 20 mg QD, 14 days</td>
<td class="Botrule" align="center" valign="top">↓19%</td>
<td class="Botrule" align="center" valign="top">↑7%</td>
</tr>
</tbody>
</table>
<a name="id_5e2ae833-f2c1-4f7d-bc79-5393dd10ae85"></a><table width="851.000">
<caption><span>Table 5: Effect of Ezetimibe Coadministration on Systemic Exposure to Other Drugs</span></caption>
<col width="43.6%">
<col width="18.8%">
<col width="20.8%">
<col width="16.8%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="top"><span class="Bold">Coadministered Drug and its Dosage Regimen</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Ezetimibe Dosage Regimen</span></td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Change in AUC</span></p>
<span class="Bold">of Coadministered Drug</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Change in C<span class="Sub">max</span></span></p>
<span class="Bold">of Coadministered Drug</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>See <a href="#i4i_interactions_id_17d5727c-55f6-44ae-b147-fc817a4cbc0d">7. Drug Interactions</a>
</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Warfarin, 25 mg single dose on Day 7 </td>
<td class="Botrule" align="left" valign="top">10 mg QD, 11 days </td>
<td class="Botrule" align="center" valign="top">
<p class="First">↓2% (R-warfarin)</p>↓4% (S-warfarin)</td>
<td class="Botrule" align="center" valign="top">
<p class="First">↑3% (R-warfarin)</p>↑1% (S-warfarin)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Digoxin, 0.5 mg single dose</td>
<td class="Botrule" align="left" valign="top">10 mg QD, 8 days</td>
<td class="Botrule" align="center" valign="top">↑2%</td>
<td class="Botrule" align="center" valign="top">↓7%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Gemfibrozil, 600 mg BID, 7 days<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Botrule" align="left" valign="top">10 mg QD, 7 days</td>
<td class="Botrule" align="center" valign="top">↓1%</td>
<td class="Botrule" align="center" valign="top">↓11%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ethinyl estradiol &amp; Levonorgestrel, QD, 21 days</td>
<td class="Botrule" align="left" valign="top">10 mg QD, Days 8-14 of 21 day oral contraceptive cycle</td>
<td class="Botrule" align="center" valign="top">
<p class="First">Ethinyl estradiol</p>
<p>0%</p>
<p>Levonorgestrel</p>0%</td>
<td class="Botrule" align="center" valign="top">
<p class="First">Ethinyl estradiol</p>
<p>↓9%</p>
<p>Levonorgestrel</p>↓5%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Glipizide, 10 mg on Days 1 and 9</td>
<td class="Botrule" align="left" valign="top">10 mg QD, Days 2-9</td>
<td class="Botrule" align="center" valign="top">↓3%</td>
<td class="Botrule" align="center" valign="top">↓5%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Fenofibrate, 200 mg QD, 14 days<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Botrule" align="left" valign="top">10 mg QD, 14 days</td>
<td class="Botrule" align="center" valign="top">↑11%</td>
<td class="Botrule" align="center" valign="top">↑7%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Cyclosporine, 100 mg single dose Day 7<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Botrule" align="left" valign="top">20 mg QD, 8 days</td>
<td class="Botrule" align="center" valign="top">↑15%</td>
<td class="Botrule" align="center" valign="top">↑10%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Statins</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    Lovastatin 20 mg QD, 7 days</td>
<td class="Botrule" align="left" valign="top">10 mg QD, 7 days</td>
<td class="Botrule" align="center" valign="top">↑19%</td>
<td class="Botrule" align="center" valign="top">↑3%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    Pravastatin 20 mg QD, 14 days</td>
<td class="Botrule" align="left" valign="top">10 mg QD, 14 days</td>
<td class="Botrule" align="center" valign="top">↓20%</td>
<td class="Botrule" align="center" valign="top">↓24%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    Atorvastatin 10 mg QD, 14 days</td>
<td class="Botrule" align="left" valign="top">10 mg QD, 14 days</td>
<td class="Botrule" align="center" valign="top">↓4%</td>
<td class="Botrule" align="center" valign="top">↑7%</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    Rosuvastatin 10 mg QD, 14 days</td>
<td class="Botrule" align="left" valign="top">10 mg QD, 14 days</td>
<td class="Botrule" align="center" valign="top">↑19%</td>
<td class="Botrule" align="center" valign="top">↑17%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">    Fluvastatin 20 mg QD, 14 days</td>
<td class="Botrule" align="left" valign="top">10 mg QD, 14 days</td>
<td class="Botrule" align="center" valign="top">↓39%</td>
<td class="Botrule" align="center" valign="top">↓27%</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Simvastatin</span></p>
<a name="id_804a3f65-679f-476b-a255-48f35117ebd9"></a><table width="862.000">
<caption><span>Table 6: Effect of Coadministered Drugs or Grapefruit Juice on Simvastatin Systemic Exposure</span></caption>
<col width="16.4%">
<col width="19.4%">
<col width="17.2%">
<col width="18.6%">
<col width="11.9%">
<col width="16.6%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="top"><span class="Bold">Coadministered Drug or Grapefruit Juice</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><span class="Bold">Dosing of Coadministered Drug or Grapefruit Juice</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><span class="Bold">Dosing of Simvastatin</span></td>
<td class="Botrule" align="center" colspan="3" valign="top">
<p class="First"><span class="Bold">Geometric Mean Ratio</span></p>
<p><span class="Bold">(Ratio
                                       </span><span class="Bold"> with / without <br>coadministered drug)</span></p>
<span class="Bold">No Effect = 1.00</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">AUC</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">C<span class="Sub">max</span></span></td>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Results could be representative of the following CYP3A4 inhibitors: ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Simvastatin acid refers to the β-hydroxyacid of simvastatin.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>The effect of amounts of grapefruit juice between those used in these two studies on simvastatin pharmacokinetics has not been studied.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Bold">Contraindicated with VYTORIN </span><span class="Italics">[see <span class="Italics"><span class="Italics"><a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4) </a></span>and </span><a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>]</span>
</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Telithromycin<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg QD for 4 days</td>
<td class="Botrule Rrule" align="center" valign="top">80 mg</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a><br>  simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">12<br>8.9</td>
<td class="Botrule" align="center" valign="top">15<br>5.3</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Nelfinavir<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">1250 mg BID for 14 days</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg QD for 28 days</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<a href="#footnote-5" class="Sup">†</a><br>  simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">
<br>6</td>
<td class="Botrule" align="center" valign="top">
<br>6.2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Itraconazole<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg QD for 4 days</td>
<td class="Botrule Rrule" align="center" valign="top">80 mg</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<a href="#footnote-5" class="Sup">†</a><br>  simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">
<p class="First">13.1</p>13.1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Posaconazole</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">100 mg (oral suspension) QD for 13 days<br><br>200 mg (oral suspension) QD for 13 days</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">40 mg<br><br><br></p>
<p><br>40 mg</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">  simvastatin acid<a href="#footnote-5" class="Sup">†</a><br>  simvastatin <br><br><br>  simvastatin acid<a href="#footnote-5" class="Sup">†</a></p>
<p>  simvastatin</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">7.3<br>10.3<br><br></p>
<p><br>8.5<br>10.6</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">9.2<br>9.4<br><br></p>
<p><br>9.5<br>11.4</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Gemfibrozil</td>
<td class="Botrule Rrule" align="center" valign="top">600 mg BID for 3 days</td>
<td class="Botrule Rrule" align="center" valign="top">40 mg</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<a href="#footnote-5" class="Sup">†</a><br>  simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">2.85</p>1.35</td>
<td class="Botrule" align="center" valign="top">
<p class="First">2.18</p>0.91</td>
</tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid &gt;1 quart of grapefruit juice with VYTORIN </span><span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>]</span>
</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">   Grapefruit Juice<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a></p>   (high dose)</td>
<td class="Botrule Rrule" align="center" valign="top">200 mL of double-strength TID
                                 </td>
<td class="Botrule Rrule" align="center" valign="top">60 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<br>  simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">7<br>16</td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">   Grapefruit Juice<a href="#footnote-6" class="Sup">‡</a></p>   (low dose)</td>
<td class="Botrule Rrule" align="center" valign="top">8 oz (about 237 mL) of single-strength
                                 </td>
<td class="Botrule Rrule" align="center" valign="top">20 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<br>  simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">1.3<br>1.9</td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid taking with &gt;10/10 mg VYTORIN, </span>based on clinical and/or post-marketing simvastatin experience  <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>]</span>
</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Verapamil SR</td>
<td class="Botrule Rrule" align="center" valign="top">240 mg QD Days 1-7 then 240 mg BID on Days 8-10</td>
<td class="Botrule Rrule" align="center" valign="top">80 mg on Day 10</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<br>  simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">2.3<br>2.5</td>
<td class="Botrule" align="center" valign="top">2.4<br>2.1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Diltiazem</td>
<td class="Botrule Rrule" align="center" valign="top">120 mg BID for 10 days</td>
<td class="Botrule Rrule" align="center" valign="top">80 mg on Day 10</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<br>  simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">2.69<br>3.10</td>
<td class="Botrule" align="center" valign="top">2.69<br>2.88</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Diltiazem</td>
<td class="Botrule Rrule" align="center" valign="top">120 mg BID for 14 days</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg on Day 14</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">4.6</td>
<td class="Botrule" align="center" valign="top">3.6</td>
</tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Bold">Avoid taking with &gt;10/20 mg VYTORIN</span>, based on clinical and/or post-marketing simvastatin experience <span class="Italics">[see <a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a>]</span>
</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Amiodarone</td>
<td class="Botrule Rrule" align="center" valign="top">400 mg QD for 3 days</td>
<td class="Botrule Rrule" align="center" valign="top">40 mg on Day 3</td>
<td class="Botrule Rrule" align="left" valign="top">simvastatin acid<br>  simvastatin </td>
<td class="Botrule Rrule" align="center" valign="top">1.75<br>1.76</td>
<td class="Botrule Lrule" align="center" valign="top">1.72<br>1.79</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Amlodipine</td>
<td class="Botrule Rrule" align="center" valign="top">10 mg QD for 10 days</td>
<td class="Botrule Rrule" align="center" valign="top">80 mg on Day 10</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<br>  simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">1.58<br>1.77</td>
<td class="Botrule" align="center" valign="top">1.56<br>1.47</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Ranolazine SR</td>
<td class="Botrule Rrule" align="center" valign="top">1000 mg BID for 7 days</td>
<td class="Botrule Rrule" align="center" valign="top">80 mg on Day 1 and Days 6-9</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<br>  simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">2.26<br>1.86</td>
<td class="Botrule" align="center" valign="top">2.28<br>1.75</td>
</tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top"><span class="Bold">No dosing adjustments required for the following:</span></td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">   Fenofibrate</td>
<td class="Botrule Rrule" align="center" valign="top">160 mg QD for 14 days</td>
<td class="Botrule Rrule" align="center" valign="top">80 mg QD on Days 8-14</td>
<td class="Botrule Rrule" align="left" valign="top">  simvastatin acid<br>  simvastatin</td>
<td class="Botrule Rrule" align="center" valign="top">0.64<br>0.89</td>
<td class="Botrule" align="center" valign="top">0.89<br>0.83</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">   Propranolol</td>
<td class="Rrule" align="center" valign="top">80 mg single dose</td>
<td class="Rrule" align="center" valign="top">80 mg single dose</td>
<td class="Rrule" align="left" valign="top">  total inhibitor<br><br>  active inhibitor</td>
<td class="Rrule" align="center" valign="top">0.79<br><br>0.79</td>
<td class="Botrule" align="center" valign="top">↓ from 33.6 to 21.1 ng∙eq/mL<br>↓ from 7.0 to 4.7 ng∙eq/mL</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_172a5edc-25a6-4554-9ca7-15e34d5d590b"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_4a90c0a4-4c36-4aa7-aeb0-43205a612d33"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">VYTORIN</span></p>
<p>No animal carcinogenicity or fertility studies have been conducted with the combination of ezetimibe and simvastatin. The combination of ezetimibe with simvastatin did not show evidence of mutagenicity <span class="Italics">in vitro</span> in a microbial mutagenicity (Ames) test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium </span>and <span class="Italics">Escherichia coli </span>with or without metabolic activation. No evidence of clastogenicity was observed <span class="Italics">in vitro</span> in a chromosomal aberration assay in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> with ezetimibe and simvastatin with or without metabolic activation. There was no evidence of genotoxicity at doses up to 600 mg/kg with the combination of ezetimibe and simvastatin (1:1) in the <span class="Italics">in vivo</span> mouse micronucleus test.</p>
<p><span class="Italics">Ezetimibe</span></p>
<p>A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC<span class="Sub">0-24hr</span> for total ezetimibe). A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (&gt;150 times the human exposure at 10 mg daily based on AUC<span class="Sub">0-24hr </span>for total ezetimibe). There were no statistically significant increases in tumor incidences in drug-treated rats or mice. </p>
<p>No evidence of mutagenicity was observed <span class="Italics">in vitro</span> in a microbial mutagenicity (Ames) test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and <span class="Italics">Escherichia coli</span> with or without metabolic activation. No evidence of clastogenicity was observed <span class="Italics">in vitro</span> in a chromosomal aberration assay in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> with or without metabolic activation. In addition, there was no evidence of genotoxicity in the <span class="Italics">in vivo</span> mouse micronucleus test.</p>
<p>In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC<span class="Sub">0-24hr</span> for total ezetimibe).</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>In a 72-week carcinogenicity study, mice were administered daily doses of simvastatin of 25, 100, and 400 mg/kg body weight, which resulted in mean plasma drug levels approximately 1, 4, and 8 times higher than the mean human plasma drug level, respectively, (as total inhibitory activity based on AUC) after an 80-mg oral dose. <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">Liver carcinomas</span> were significantly increased in high-dose females and mid- and high-dose males with a maximum incidence of 90% in males. The incidence of <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of the liver was significantly increased in mid- and high-dose females. Drug treatment also significantly increased the incidence of lung <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in mid- and high-dose males and females. <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">Adenomas</span> of the Harderian gland (a gland of the eye of rodents) were significantly higher in high-dose mice than in controls. No evidence of a tumorigenic effect was observed at 25 mg/kg/day. </p>
<p>In a separate 92-week carcinogenicity study in mice at doses up to 25 mg/kg/day, no evidence of a tumorigenic effect was observed (mean plasma drug levels were 1 times higher than humans given 80 mg simvastatin as measured by AUC).</p>
<p>In a two-year study in rats at 25 mg/kg/day, there was a statistically significant increase in the incidence of thyroid follicular <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in female rats exposed to approximately 11 times higher levels of simvastatin than in humans given 80 mg simvastatin (as measured by AUC).</p>
<p>A second two-year rat carcinogenicity study with doses of 50 and 100 mg/kg/day produced <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and carcinomas (in female rats at both doses and in males at 100 mg/kg/day). Thyroid follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were increased in males and females at both doses; thyroid follicular cell carcinomas were increased in females at 100 mg/kg/day. The increased incidence of thyroid neoplasms appears to be consistent with findings from other statins. These treatment levels represented plasma drug levels (AUC) of approximately 7 and 15 times (males) and 22 and 25 times (females) the mean human plasma drug exposure after an 80-mg daily dose.</p>
<p>No evidence of mutagenicity was observed in a microbial mutagenicity (Ames) test with or without rat or mouse liver metabolic activation. In addition, no evidence of damage to genetic material was noted in an <span class="Italics">in vitro</span> alkaline elution assay using rat hepatocytes, a V-79 mammalian cell forward mutation study, an <span class="Italics">in vitro</span> chromosome aberration study in CHO cells, or an <span class="Italics">in vivo</span> chromosomal aberration assay in mouse bone marrow.</p>
<p>There was decreased fertility in male rats treated with simvastatin for 34 weeks at 25 mg/kg body weight (4 times the maximum human exposure level, based on AUC, in patients receiving 80 mg/day); however, this effect was not observed during a subsequent fertility study in which simvastatin was administered at this same dose level to male rats for 11 weeks (the entire cycle of spermatogenesis including epididymal maturation). No microscopic changes were observed in the testes of rats from either study. At 180 mg/kg/day (which produces exposure levels 22 times higher than those in humans taking 80 mg/day based on surface area, mg/m<span class="Sup">2</span>), seminiferous tubule degeneration (<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and loss of spermatogenic epithelium) was observed. In dogs, there was drug-related <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>, decreased spermatogenesis, spermatocytic degeneration and giant cell formation at 10 mg/kg/day (approximately 2 times the human exposure, based on AUC, at 80 mg/day). The clinical significance of these findings is unclear.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_48cdc79f-3dc3-4dcb-bccd-47a0235b2f29"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Italics"> CNS Toxicity </span></p>
<p>Optic nerve degeneration was seen in clinically normal dogs treated with simvastatin for 14 weeks at 180 mg/kg/day, a dose that produced mean plasma drug levels about 12 times higher than the mean plasma drug level in humans taking 80 mg/day.</p>
<p>A chemically similar drug in this class also produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion starting at 60 mg/kg/day, a dose that produced mean plasma drug levels about 30 times higher than the mean plasma drug level in humans taking the highest recommended dose (as measured by total enzyme inhibitory activity). This same drug also produced vestibulocochlear Wallerian-like degeneration and retinal <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> cell chromatolysis in dogs treated for 14 weeks at 180 mg/kg/day, a dose that resulted in a mean plasma drug level similar to that seen with the 60 mg/kg/day dose.</p>
<p>CNS vascular lesions, characterized by perivascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, mononuclear cell infiltration of perivascular spaces, perivascular fibrin deposits and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of small vessels, were seen in dogs treated with simvastatin at a dose of 360 mg/kg/day, a dose that produced mean plasma drug levels that were about 14 times higher than the mean plasma drug levels in humans taking 80 mg/day. Similar CNS vascular lesions have been observed with several other drugs of this class.</p>
<p>There were <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> in female rats after two years of treatment with 50 and 100 mg/kg/day (22 and 25 times the human AUC at 80 mg/day, respectively) and in dogs after three months at 90 mg/kg/day (19 times) and at two years at 50 mg/kg/day (5 times).</p>
<p><br><span class="Italics">Ezetimibe</span></p>
<p>The hypocholesterolemic effect of ezetimibe was evaluated in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-fed Rhesus monkeys, dogs, rats, and mouse models of human <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> metabolism. Ezetimibe was found to have an ED<span class="Sub">50</span> value of 0.5 μg/kg/day for inhibiting the rise in plasma <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels in monkeys. The ED<span class="Sub">50</span> values in dogs, rats, and mice were 7, 30, and 700 μg/kg/day, respectively. These results are consistent with ezetimibe being a potent <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption inhibitor.</p>
<p>In a rat model, where the glucuronide metabolite of ezetimibe (ezetimibe-glucuronide) was administered intraduodenally, the metabolite was as potent as ezetimibe in inhibiting the absorption of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, suggesting that the glucuronide metabolite had activity similar to the parent drug.</p>
<p>In 1-month studies in dogs given ezetimibe (0.03 to 300 mg/kg/day), the concentration of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in gallbladder bile increased ~2- to 4-fold. However, a dose of 300 mg/kg/day administered to dogs for one year did not result in gallstone formation or any other adverse hepatobiliary effects. In a 14-day study in mice given ezetimibe (0.3 to 5 mg/kg/day) and fed a low-fat or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-rich diet, the concentration of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in gallbladder bile was either unaffected or reduced to normal levels, respectively.</p>
<p>A series of acute preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption. Ezetimibe inhibited the absorption of <span class="Sup">14</span>C-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> with no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or the fat-soluble vitamins A and D.</p>
<p>In 4- to 12-week toxicity studies in mice, ezetimibe did not induce cytochrome P450 drug-metabolizing enzymes. In toxicity studies, a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> of ezetimibe with statins (parents or their active hydroxy acid metabolites) was seen in rats, dogs, and rabbits.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_0602b924-dad1-4885-b8d9-561a92765138"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_702a11d0-45c8-4989-9965-71b6dc40104a"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></h2>
<p class="First"><span class="Italics">VYTORIN</span></p>
<p>VYTORIN reduces total-C, LDL-C, Apo B, TG, and non-HDL-C, and increases HDL-C in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. Maximal to near maximal response is generally achieved within 2 weeks and maintained during chronic therapy.</p>
<p>VYTORIN is effective in men and women with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. Experience in non-Caucasians is limited and does not permit a precise estimate of the magnitude of the effects of VYTORIN.</p>
<p>Five multicenter, double-blind studies conducted with either VYTORIN or coadministered ezetimibe and simvastatin equivalent to VYTORIN in patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> are reported: two were comparisons with simvastatin, two were comparisons with atorvastatin, and one was a comparison with rosuvastatin.</p>
<p>In a multicenter, double-blind, placebo-controlled, 12-week trial, 1528 hyperlipidemic patients were randomized to one of ten treatment groups: placebo, ezetimibe (10 mg), simvastatin (10 mg, 20 mg, 40 mg, or 80 mg), or VYTORIN (10/10, 10/20, 10/40, or 10/80).</p>
<p>When patients receiving VYTORIN were compared to those receiving all doses of simvastatin, VYTORIN significantly lowered total-C, LDL-C, Apo B, TG, and non-HDL-C. The effects of VYTORIN on HDL-C were similar to the effects seen with simvastatin. Further analysis showed VYTORIN significantly increased HDL-C compared with placebo. (See Table 7.) The lipid response to VYTORIN was similar in patients with TG levels greater than or less than 200 mg/dL.</p>
<a name="id_2fe7e541-a32e-4233-8026-2821be109dfb"></a><table width="701.000">
<caption><span>Table 7: Response to VYTORIN in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a> % Change from Untreated Baseline)</span></caption>
<col width="29.2%">
<col width="9.7%">
<col width="9.7%">
<col width="9.7%">
<col width="9.7%">
<col width="9.7%">
<col width="10.7%">
<col width="11.6%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="bottom">Treatment<br>(Daily Dose)</td>
<td class="Botrule" align="center" valign="bottom">N</td>
<td class="Botrule" align="center" valign="bottom">Total-C</td>
<td class="Botrule" align="center" valign="bottom">LDL-C</td>
<td class="Botrule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></td>
<td class="Botrule" align="center" valign="bottom">HDL-C</td>
<td class="Botrule" align="center" valign="bottom">TG<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="bottom">Non-HDL-C</td>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>For triglycerides, median % change from baseline</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>VYTORIN doses pooled (10/10-10/80) significantly reduced total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, TG, and non-HDL-C compared to simvastatin and significantly increased HDL-C compared to placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="middle">Pooled data (All VYTORIN doses)<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">609</td>
<td class="Botrule" align="center" valign="middle">-38</td>
<td class="Botrule" align="center" valign="middle">-53</td>
<td class="Botrule" align="center" valign="middle">-42</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-24</td>
<td class="Botrule" align="center" valign="middle">-49</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Pooled data (All simvastatin doses)<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">622</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">-39</td>
<td class="Botrule" align="center" valign="middle">-32</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-21</td>
<td class="Botrule" align="center" valign="middle">-36</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Ezetimibe 10 mg</td>
<td class="Botrule" align="center" valign="middle">149</td>
<td class="Botrule" align="center" valign="middle">-13</td>
<td class="Botrule" align="center" valign="middle">-19</td>
<td class="Botrule" align="center" valign="middle">-15</td>
<td class="Botrule" align="center" valign="middle">+5</td>
<td class="Botrule" align="center" valign="middle">-11</td>
<td class="Botrule" align="center" valign="middle">-18</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Placebo</td>
<td class="Botrule" align="center" valign="middle">148</td>
<td class="Botrule" align="center" valign="middle">-1</td>
<td class="Botrule" align="center" valign="middle">-2</td>
<td class="Botrule" align="center" valign="middle">0</td>
<td class="Botrule" align="center" valign="middle">0</td>
<td class="Botrule" align="center" valign="middle">-2</td>
<td class="Botrule" align="center" valign="middle">-2</td>
</tr>
<tr>
<td align="left" valign="middle">VYTORIN by dose</td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/10</td>
<td class="Botrule" align="center" valign="middle">152</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">-45</td>
<td class="Botrule" align="center" valign="middle">-35</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-23</td>
<td class="Botrule" align="center" valign="middle">-41</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/20</td>
<td class="Botrule" align="center" valign="middle">156</td>
<td class="Botrule" align="center" valign="middle">-36</td>
<td class="Botrule" align="center" valign="middle">-52</td>
<td class="Botrule" align="center" valign="middle">-41</td>
<td class="Botrule" align="center" valign="middle">+10</td>
<td class="Botrule" align="center" valign="middle">-24</td>
<td class="Botrule" align="center" valign="middle">-47</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/40</td>
<td class="Botrule" align="center" valign="middle">147</td>
<td class="Botrule" align="center" valign="middle">-39</td>
<td class="Botrule" align="center" valign="middle">-55</td>
<td class="Botrule" align="center" valign="middle">-44</td>
<td class="Botrule" align="center" valign="middle">+6</td>
<td class="Botrule" align="center" valign="middle">-23</td>
<td class="Botrule" align="center" valign="middle">-51</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/80</td>
<td class="Botrule" align="center" valign="middle">154</td>
<td class="Botrule" align="center" valign="middle">-43</td>
<td class="Botrule" align="center" valign="middle">-60</td>
<td class="Botrule" align="center" valign="middle">-49</td>
<td class="Botrule" align="center" valign="middle">+6</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">-56</td>
</tr>
<tr>
<td align="left" valign="middle">Simvastatin by dose</td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10 mg</td>
<td class="Botrule" align="center" valign="middle">158</td>
<td class="Botrule" align="center" valign="middle">-23</td>
<td class="Botrule" align="center" valign="middle">-33</td>
<td class="Botrule" align="center" valign="middle">-26</td>
<td class="Botrule" align="center" valign="middle">+5</td>
<td class="Botrule" align="center" valign="middle">-17</td>
<td class="Botrule" align="center" valign="middle">-30</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">20 mg</td>
<td class="Botrule" align="center" valign="middle">150</td>
<td class="Botrule" align="center" valign="middle">-24</td>
<td class="Botrule" align="center" valign="middle">-34</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-18</td>
<td class="Botrule" align="center" valign="middle">-32</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">40 mg</td>
<td class="Botrule" align="center" valign="middle">156</td>
<td class="Botrule" align="center" valign="middle">-29</td>
<td class="Botrule" align="center" valign="middle">-41</td>
<td class="Botrule" align="center" valign="middle">-33</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-21</td>
<td class="Botrule" align="center" valign="middle">-38</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">80 mg</td>
<td class="Botrule" align="center" valign="middle">158</td>
<td class="Botrule" align="center" valign="middle">-35</td>
<td class="Botrule" align="center" valign="middle">-49</td>
<td class="Botrule" align="center" valign="middle">-39</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-27</td>
<td class="Botrule" align="center" valign="middle">-45</td>
</tr>
</tbody>
</table>
<p>In a multicenter, double-blind, controlled, 23-week study, 710 patients with known CHD or CHD risk equivalents, as defined by the NCEP ATP III guidelines, and an LDL-C ≥130 mg/dL were randomized to one of four treatment groups: coadministered ezetimibe and simvastatin equivalent to VYTORIN (10/10, 10/20, and 10/40) or simvastatin 20 mg. Patients not reaching an LDL-C &lt;100 mg/dL had their simvastatin dose titrated at 6-week intervals to a maximal dose of 80 mg.</p>
<p>At Week 5, the LDL-C reductions with VYTORIN 10/10, 10/20, or 10/40 were significantly larger than with simvastatin 20 mg (see Table 8).</p>
<a name="id_ba46bd8a-0663-482c-aa71-06196ed6c9a3"></a><table width="482.000">
<caption><span>Table 8: Response to VYTORIN after 5 Weeks in Patients with CHD or CHD Risk Equivalents and an LDL-C ≥130 mg/dL</span></caption>
<col width="28.4%">
<col width="19.3%">
<col width="17.0%">
<col width="18.3%">
<col width="17.0%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">Simvastatin<br>20 mg</td>
<td class="Botrule" align="center" valign="middle">VYTORIN<br>10/10</td>
<td class="Botrule" align="center" valign="middle">VYTORIN<br>10/20</td>
<td class="Botrule" align="center" valign="middle">VYTORIN<br>10/40</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="middle">N</td>
<td class="Botrule" align="center" valign="middle">253</td>
<td class="Botrule" align="center" valign="middle">251</td>
<td class="Botrule" align="center" valign="middle">109</td>
<td class="Botrule" align="center" valign="middle">97</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Mean baseline<br>LDL-C</td>
<td class="Botrule" align="center" valign="middle">174</td>
<td class="Botrule" align="center" valign="middle">165</td>
<td class="Botrule" align="center" valign="middle">167</td>
<td class="Botrule" align="center" valign="middle">171</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">Percent change<br>LDL-C</td>
<td class="Botrule" align="center" valign="middle">-38</td>
<td class="Botrule" align="center" valign="middle">-47</td>
<td class="Botrule" align="center" valign="middle">-53</td>
<td class="Botrule" align="center" valign="middle">-59</td>
</tr>
</tbody>
</table>
<p>In a multicenter, double-blind, 6-week study, 1902 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, who had not met their NCEP ATP III target LDL-C goal, were randomized to one of eight treatment groups: VYTORIN (10/10, 10/20, 10/40, or 10/80) or atorvastatin (10 mg, 20 mg, 40 mg, or 80 mg).</p>
<p>Across the dosage range, when patients receiving VYTORIN were compared to those receiving milligram-equivalent statin doses of atorvastatin, VYTORIN lowered total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and non-HDL-C significantly more than atorvastatin. Only the 10/40 mg and 10/80 mg VYTORIN doses increased HDL-C significantly more than the corresponding milligram-equivalent statin dose of atorvastatin. The effects of VYTORIN on TG were similar to the effects seen with atorvastatin. (See Table 9.)</p>
<a name="id_baf64c35-ddaf-48cf-bc1f-2bd543fe7422"></a><table width="637.000">
<caption><span>Table 9: Response to VYTORIN and Atorvastatin in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a> % Change from Untreated Baseline) </span></caption>
<col width="22.4%">
<col width="10.4%">
<col width="11.1%">
<col width="10.4%">
<col width="10.4%">
<col width="10.4%">
<col width="11.1%">
<col width="13.8%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="bottom">Treatment<br>(Daily Dose)</td>
<td class="Botrule" align="center" valign="bottom">N</td>
<td class="Botrule" align="center" valign="bottom">Total-C<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="bottom">LDL-C<a href="#footnote-10" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span><a href="#footnote-10" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="bottom">HDL-C</td>
<td class="Botrule" align="center" valign="bottom">TG<a href="#footnote-9" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="bottom">Non-HDL-C<a href="#footnote-10" class="Sup">†</a>
</td>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>For triglycerides, median % change from baseline</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>VYTORIN doses pooled (10/10-10/80) provided significantly greater reductions in total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and non-HDL-C compared to atorvastatin doses pooled (10-80).</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>p&lt;0.05 for difference with atorvastatin at equal mg doses of the simvastatin component</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="middle">VYTORIN by dose</td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/10</td>
<td class="Botrule" align="center" valign="middle">230</td>
<td class="Botrule" align="center" valign="middle">-34<a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">-47<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">-37<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-26</td>
<td class="Botrule" align="center" valign="middle">-43<a href="#footnote-11" class="Sup">‡</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/20</td>
<td class="Botrule" align="center" valign="middle">233</td>
<td class="Botrule" align="center" valign="middle">-37<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">-51<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">-40<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-25</td>
<td class="Botrule" align="center" valign="middle">-46<a href="#footnote-11" class="Sup">‡</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/40</td>
<td class="Botrule" align="center" valign="middle">236</td>
<td class="Botrule" align="center" valign="middle">-41<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">-57<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">-46<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">+9<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">-27</td>
<td class="Botrule" align="center" valign="middle">-52<a href="#footnote-11" class="Sup">‡</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/80</td>
<td class="Botrule" align="center" valign="middle">224</td>
<td class="Botrule" align="center" valign="middle">-43<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">-59<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">-48<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">+8<a href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">-54<a href="#footnote-11" class="Sup">‡</a>
</td>
</tr>
<tr>
<td align="left" valign="middle">Atorvastatin by dose</td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10 mg</td>
<td class="Botrule" align="center" valign="middle">235</td>
<td class="Botrule" align="center" valign="middle">-27</td>
<td class="Botrule" align="center" valign="middle">-36</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-21</td>
<td class="Botrule" align="center" valign="middle">-34</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">20 mg</td>
<td class="Botrule" align="center" valign="middle">230</td>
<td class="Botrule" align="center" valign="middle">-32</td>
<td class="Botrule" align="center" valign="middle">-44</td>
<td class="Botrule" align="center" valign="middle">-37</td>
<td class="Botrule" align="center" valign="middle">+5</td>
<td class="Botrule" align="center" valign="middle">-25</td>
<td class="Botrule" align="center" valign="middle">-41</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">40 mg</td>
<td class="Botrule" align="center" valign="middle">232</td>
<td class="Botrule" align="center" valign="middle">-36</td>
<td class="Botrule" align="center" valign="middle">-48</td>
<td class="Botrule" align="center" valign="middle">-40</td>
<td class="Botrule" align="center" valign="middle">+4</td>
<td class="Botrule" align="center" valign="middle">-24</td>
<td class="Botrule" align="center" valign="middle">-45</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">80 mg</td>
<td class="Botrule" align="center" valign="middle">230</td>
<td class="Botrule" align="center" valign="middle">-40</td>
<td class="Botrule" align="center" valign="middle">-53</td>
<td class="Botrule" align="center" valign="middle">-44</td>
<td class="Botrule" align="center" valign="middle">+1</td>
<td class="Botrule" align="center" valign="middle">-32</td>
<td class="Botrule" align="center" valign="middle">-50</td>
</tr>
</tbody>
</table>
<p>In a multicenter, double-blind, 24-week, forced-titration study, 788 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, who had not met their NCEP ATP III target LDL-C goal, were randomized to receive coadministered ezetimibe and simvastatin equivalent to VYTORIN (10/10 and 10/20) or atorvastatin 10 mg. For all three treatment groups, the dose of the statin was titrated at 6-week intervals to 80 mg. At each pre-specified dose comparison, VYTORIN lowered LDL-C to a greater degree than atorvastatin (see Table 10). </p>
<a name="id_85b85637-9641-41a8-b5cf-7f7566339992"></a><table width="752.000">
<caption><span>Table 10: Response to VYTORIN and Atorvastatin in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean<a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a> % Change from Untreated Baseline)</span></caption>
<col width="21.1%">
<col width="8.8%">
<col width="9.4%">
<col width="10.2%">
<col width="11.7%">
<col width="12.4%">
<col width="13.2%">
<col width="13.2%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="bottom">Treatment</td>
<td class="Botrule" align="center" valign="bottom">N</td>
<td class="Botrule" align="center" valign="bottom">Total-C</td>
<td class="Botrule" align="center" valign="bottom">LDL-C</td>
<td class="Botrule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></td>
<td class="Botrule" align="center" valign="bottom">HDL-C</td>
<td class="Botrule" align="center" valign="bottom">TG<a href="#footnote-12" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="bottom">Non-HDL-C</td>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>For triglycerides, median % change from baseline</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">†</a></dt>
<dd>p≤0.05 for difference with atorvastatin in the specified week</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">‡</a></dt>
<dd>Data pooled for common doses of VYTORIN at Weeks 18 and 24.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="middle">Week 6</td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Atorvastatin 10 mg
                                 </td>
<td class="Botrule" align="center" valign="middle">262</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">-37</td>
<td class="Botrule" align="center" valign="middle">-32</td>
<td class="Botrule" align="center" valign="middle">+5</td>
<td class="Botrule" align="center" valign="middle">-23</td>
<td class="Botrule" align="center" valign="middle">-35</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN10/10
                                 </td>
<td class="Botrule" align="center" valign="middle">263</td>
<td class="Botrule" align="center" valign="middle">-34<a name="footnote-reference-13" href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-46<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-38<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">+8<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-26</td>
<td class="Botrule" align="center" valign="middle">-43<a href="#footnote-13" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN 10/20
                                 </td>
<td class="Botrule" align="center" valign="middle">263</td>
<td class="Botrule" align="center" valign="middle">-36<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-50<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-41<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">+10<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-25</td>
<td class="Botrule" align="center" valign="middle">-46<a href="#footnote-13" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Week 12</td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Atorvastatin 20 mg</td>
<td class="Botrule" align="center" valign="middle">246</td>
<td class="Botrule" align="center" valign="middle">-33</td>
<td class="Botrule" align="center" valign="middle">-44</td>
<td class="Botrule" align="center" valign="middle">-38</td>
<td class="Botrule" align="center" valign="middle">+7</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">-42</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN 10/20</td>
<td class="Botrule" align="center" valign="middle">250</td>
<td class="Botrule" align="center" valign="middle">-37<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-50<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-41<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">+9</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">-46<a href="#footnote-13" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN 10/40</td>
<td class="Botrule" align="center" valign="middle">252</td>
<td class="Botrule" align="center" valign="middle">-39<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-54<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-45<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">+12<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">-50<a href="#footnote-13" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Week 18</td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Atorvastatin 40 mg</td>
<td class="Botrule" align="center" valign="middle">237</td>
<td class="Botrule" align="center" valign="middle">-37</td>
<td class="Botrule" align="center" valign="middle">-49</td>
<td class="Botrule" align="center" valign="middle">-42</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-31</td>
<td class="Botrule" align="center" valign="middle">-47</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN 10/40<a name="footnote-reference-14" href="#footnote-14" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">482</td>
<td class="Botrule" align="center" valign="middle">-40<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-56<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-45<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">+11<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-32</td>
<td class="Botrule" align="center" valign="middle">-52<a href="#footnote-13" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Week 24</td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Atorvastatin 80 mg</td>
<td class="Botrule" align="center" valign="middle">228</td>
<td class="Botrule" align="center" valign="middle">-40</td>
<td class="Botrule" align="center" valign="middle">-53</td>
<td class="Botrule" align="center" valign="middle">-45</td>
<td class="Botrule" align="center" valign="middle">+6</td>
<td class="Botrule" align="center" valign="middle">-35</td>
<td class="Botrule" align="center" valign="middle">-50</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">VYTORIN 10/80<a href="#footnote-14" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="middle">459</td>
<td class="Botrule" align="center" valign="middle">-43<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-59<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-49<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">+12<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="middle">-35</td>
<td class="Botrule" align="center" valign="middle">-55<a href="#footnote-13" class="Sup">†</a>
</td>
</tr>
</tbody>
</table>
<p>In a multicenter, double-blind, 6-week study, 2959 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, who had not met their NCEP ATP III target LDL-C goal, were randomized to one of six treatment groups: VYTORIN (10/20, 10/40, or 10/80) or rosuvastatin (10 mg, 20 mg, or 40 mg).</p>
<p>The effects of VYTORIN and rosuvastatin on total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, TG, non-HDL-C and HDL-C are shown in Table 11.</p>
<a name="id_7fd2fae2-114f-40d1-a130-3aed6a663fca"></a><table width="642.000">
<caption><span>Table 11: Response to VYTORIN and Rosuvastatin in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a> % Change from Untreated Baseline)</span></caption>
<col width="22.3%">
<col width="12.0%">
<col width="11.1%">
<col width="10.3%">
<col width="11.1%">
<col width="10.3%">
<col width="11.1%">
<col width="12.0%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="bottom">Treatment<br>(Daily Dose)</td>
<td class="Botrule" align="center" valign="bottom">N</td>
<td class="Botrule" align="center" valign="bottom">Total-C<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="bottom">LDL-C<a href="#footnote-16" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span><a href="#footnote-16" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="bottom">HDL-C</td>
<td class="Botrule" align="center" valign="bottom">TG<a href="#footnote-15" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="bottom">Non-HDL-C<a href="#footnote-16" class="Sup">†</a>
</td>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>For triglycerides, median % change from baseline</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>VYTORIN doses pooled (10/20-10/80) provided significantly greater reductions in total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and non-HDL-C compared to rosuvastatin doses pooled (10-40 mg).</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd>p&lt;0.05 vs. rosuvastatin 10 mg</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">§</a></dt>
<dd>p&lt;0.05 vs. rosuvastatin 20 mg</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">¶</a></dt>
<dd> p&lt;0.05 vs. rosuvastatin 40 mg</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">VYTORIN by dose<br>10/20</td>
<td class="Botrule" align="center" valign="bottom">476</td>
<td class="Botrule" align="center" valign="bottom">-37<a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="bottom">-52<a href="#footnote-17" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="bottom">-42<a href="#footnote-17" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="bottom">+7</td>
<td class="Botrule" align="center" valign="bottom">-23<a href="#footnote-17" class="Sup">‡</a>
</td>
<td class="Botrule" align="center" valign="bottom">-47<a href="#footnote-17" class="Sup">‡</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/40</td>
<td class="Botrule" align="center" valign="middle">477</td>
<td class="Botrule" align="center" valign="middle">-39<a name="footnote-reference-18" href="#footnote-18" class="Sup">§</a>
</td>
<td class="Botrule" align="center" valign="middle">-55<a href="#footnote-18" class="Sup">§</a>
</td>
<td class="Botrule" align="center" valign="middle">-44<a href="#footnote-18" class="Sup">§</a>
</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-27</td>
<td class="Botrule" align="center" valign="middle">-50<a href="#footnote-18" class="Sup">§</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">10/80</td>
<td class="Botrule" align="center" valign="middle">474</td>
<td class="Botrule" align="center" valign="middle">-44<a name="footnote-reference-19" href="#footnote-19" class="Sup">¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-61<a href="#footnote-19" class="Sup">¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-50<a href="#footnote-19" class="Sup">¶</a>
</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-30<a href="#footnote-19" class="Sup">¶</a>
</td>
<td class="Botrule" align="center" valign="middle">-56<a href="#footnote-19" class="Sup">¶</a>
</td>
</tr>
<tr>
<td align="left" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Rosuvastatin by dose<br>10 mg</td>
<td class="Botrule" align="center" valign="bottom">475</td>
<td class="Botrule" align="center" valign="bottom">-32</td>
<td class="Botrule" align="center" valign="bottom">-46</td>
<td class="Botrule" align="center" valign="bottom">-37</td>
<td class="Botrule" align="center" valign="bottom">+7</td>
<td class="Botrule" align="center" valign="bottom">-20</td>
<td class="Botrule" align="center" valign="bottom">-42</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">20 mg</td>
<td class="Botrule" align="center" valign="middle">478</td>
<td class="Botrule" align="center" valign="middle">-37</td>
<td class="Botrule" align="center" valign="middle">-52</td>
<td class="Botrule" align="center" valign="middle">-43</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-26</td>
<td class="Botrule" align="center" valign="middle">-48</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">40 mg</td>
<td class="Botrule" align="center" valign="middle">475</td>
<td class="Botrule" align="center" valign="middle">-41</td>
<td class="Botrule" align="center" valign="middle">-57</td>
<td class="Botrule" align="center" valign="middle">-47</td>
<td class="Botrule" align="center" valign="middle">+8</td>
<td class="Botrule" align="center" valign="middle">-28</td>
<td class="Botrule" align="center" valign="middle">-52</td>
</tr>
</tbody>
</table>
<p>In a multicenter, double-blind, 24-week trial, 214 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus treated with thiazolidinediones (rosiglitazone or pioglitazone) for a minimum of 3 months and simvastatin 20 mg for a minimum of 6 weeks were randomized to receive either simvastatin 40 mg or the coadministered active ingredients equivalent to VYTORIN 10/20. The median LDL-C and HbA1c levels at baseline were 89 mg/dL and 7.1%, respectively.</p>
<p>VYTORIN 10/20 was significantly more effective than doubling the dose of simvastatin to 40 mg. The median percent changes from baseline for VYTORIN vs. simvastatin were: LDL-C -25% and -5%; total-C -16% and -5%; Apo B -19% and -5%; and non-HDL-C -23% and -5%. Results for HDL-C and TG between the two treatment groups were not significantly different.</p>
<p><br><span class="Italics">Ezetimibe</span></p>
<p>In two multicenter, double-blind, placebo-controlled, 12-week studies in 1719 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, ezetimibe significantly lowered total-C (-13%), LDL-C (-19%), Apo B (-14%), and TG (-8%), and increased HDL-C (+3%) compared to placebo. Reduction in LDL-C was consistent across age, sex, and baseline LDL-C.</p>
<p><br><span class="Italics">Simvastatin</span></p>
<p>In two large, placebo-controlled clinical trials, the Scandinavian Simvastatin Survival Study (N=4,444 patients) and the Heart Protection Study (N=20,536 patients), the effects of treatment with simvastatin were assessed in patients at high risk of coronary events because of existing coronary heart disease, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, peripheral vessel disease, history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or other cerebrovascular disease. Simvastatin was proven to reduce: the risk of total mortality by reducing CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>; the risk of non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; and the need for coronary and non-coronary revascularization procedures. </p>
<p>No incremental benefit of VYTORIN on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_86369a4c-7e3d-4194-9a31-d1c1db7cfa92"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> (HoFH)</h2>
<p class="First">A double-blind, randomized, 12-week study was performed in patients with a clinical and/or genotypic diagnosis of HoFH. Data were analyzed from a subgroup of patients (n=14) receiving simvastatin 40 mg at baseline. Increasing the dose of simvastatin from 40 to 80 mg (n=5) produced a reduction of LDL-C of 13% from baseline on simvastatin 40 mg. Coadministered ezetimibe and simvastatin equivalent to VYTORIN (10/40 and 10/80 pooled, n=9), produced a reduction of LDL-C of 23% from baseline on simvastatin 40 mg. In those patients coadministered ezetimibe and simvastatin equivalent to VYTORIN (10/80, n=5), a reduction of LDL-C of 29% from baseline on simvastatin 40 mg was produced.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic Kidney Disease</span> (CKD)</h2>
<p class="First">The Study of Heart and Renal Protection (SHARP) was a multinational, randomized, placebo-controlled, double-blind trial that investigated the effect of VYTORIN on the time to a first major vascular event (MVE) among 9438 patients with moderate to severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> (approximately one-third on dialysis at baseline) who did not have a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or coronary revascularization. An MVE was defined as nonfatal MI, cardiac <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or any revascularization procedure. Patients were allocated to treatment using a method that took into account the distribution of 8 important baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups.</p>
<p>For the first year, 9438 patients were allocated 4:4:1, to VYTORIN 10/20, placebo, or simvastatin 20 mg daily, respectively. The 1-year simvastatin arm enabled the comparison of VYTORIN to simvastatin with regard to safety and effect on lipid levels. At 1 year the simvastatin-only arm was re-allocated 1:1 to VYTORIN 10/20 or placebo. A total of 9270 patients were ever allocated to VYTORIN 10/20 (n=4650) or placebo (n=4620) during the trial. The median follow-up duration was 4.9 years. Patients had a mean age of 61 years; 63% were male, 72% were Caucasian, and 23% were diabetic; and, for those not on dialysis at baseline, the median serum creatinine was 2.5 mg/dL and the median estimated glomerular filtration rate (eGFR) was 25.6 mL/min/1.73 m<span class="Sup">2</span>, with 94% of patients having an eGFR &lt; 45 mL/min/1.73m<span class="Sup">2</span>. Eligibility did not depend on lipid levels. Mean LDL-C at baseline was 108 mg/dL. At 1 year, the mean LDL-C was 26% lower in the simvastatin arm and 38% lower in the VYTORIN arm relative to placebo. At the midpoint of the study (2.5 years), the mean LDL-C was 32% lower for VYTORIN relative to placebo. Patients no longer taking study medication were included in all lipid measurements.</p>
<p>In the primary intent-to-treat analysis, 639 (15.2%) of 4193 patients initially allocated to VYTORIN and 749 (17.9%) of 4191 patients initially allocated to placebo experienced an MVE. This corresponded to a relative risk reduction of 16% (p=0.001) (see <a href="#Fig1">Figure 1</a>). Similarly, 526 (11.3%) of 4650 patients ever allocated to VYTORIN and 619 (13.4%) of 4620 patients ever allocated to placebo experienced a major atherosclerotic event (MAE; a subset of the MVE composite that excluded non-coronary cardiac <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span>), corresponding to a relative risk reduction of 17% (p=0.002). The trial demonstrated that treatment with VYTORIN 10/20 mg versus placebo reduced the risk for MVE and MAE in this CKD population. The study design precluded drawing conclusions regarding the independent contribution of either ezetimibe or simvastatin to the observed effect.</p>
<p>The treatment effect of VYTORIN on MVE was attenuated among patients on dialysis at baseline compared with those not on dialysis at baseline. Among 3023 patients on dialysis at baseline, VYTORIN reduced the risk of MVE by 6% (RR 0.94: 95% CI 0.80-1.09) compared with 22% (RR 0.78: 95% CI 0.69-0.89) among 6247 patients not on dialysis at baseline (interaction P=0.08).</p>
<a name="i43d29a2a-2feb-4491-8d79-f9023a313e21"></a><table width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 1: Effect of VYTORIN on the Primary Endpoint of Risk of Major Vascular Events</span></td></tr>
<tr class="Botrule Last"><td align="center">
<a name="Fig1"></a><img alt="image of Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2507c644-e445-4e31-8d15-82afcb15f274&amp;name=vytorin-03.jpg">
</td></tr>
</tbody>
</table>
<p>The individual components of MVE in all patients ever allocated to VYTORIN or placebo are presented in <a href="#T12">Table 12</a>.</p>
<a name="T12"></a><table width="100%">
<caption><span>Table 12 Number of First Events for Each Component of the Major Vascular Event Composite Endpoint in SHARP<a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="10%">
<thead><tr class="First Last">
<th align="left">Outcome</th>
<th align="center">VYTORIN 10/20<br>(N=4650)</th>
<th align="center">Placebo<br>(N=4620)</th>
<th align="center">Risk Ratio<br>(95% CI)</th>
<th align="center">P-value</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>Intention-to-treat analysis on all SHARP patients ever allocated to VYTORIN or placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="left">Major Vascular Events </td>
<td align="center">701 (15.1%)</td>
<td align="center">814 (17.6%)</td>
<td align="center">0.85 (0.77-0.94)</td>
<td align="center">0.001</td>
</tr>
<tr class="Botrule">
<td align="left">  Nonfatal MI</td>
<td align="center">134 (2.9%)</td>
<td align="center">159 (3.4%)</td>
<td align="center">0.84 (0.66-1.05)</td>
<td align="center">0.12</td>
</tr>
<tr class="Botrule">
<td align="left">  Cardiac <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">253 (5.4%)</td>
<td align="center">272 (5.9%)</td>
<td align="center">0.93 (0.78-1.10)</td>
<td align="center">0.38</td>
</tr>
<tr class="Botrule">
<td align="left">  Any <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </td>
<td align="center">171 (3.7%)</td>
<td align="center">210 (4.5%)</td>
<td align="center">0.81 (0.66-0.99)</td>
<td align="center">0.038</td>
</tr>
<tr class="Botrule">
<td align="left">    Non-<span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic Stroke</span></td>
<td align="center">131 (2.8%)</td>
<td align="center">174 (3.8%)</td>
<td align="center">0.75 (0.60-0.94)</td>
<td align="center">0.011</td>
</tr>
<tr class="Botrule">
<td align="left">    <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">Hemorrhagic Stroke</span></td>
<td align="center">45 (1.0%)</td>
<td align="center">37 (0.8%)</td>
<td align="center">1.21 (0.78-1.86)</td>
<td align="center">0.40</td>
</tr>
<tr class="Last">
<td align="left">  Any Revascularization</td>
<td align="center">284 (6.1%)</td>
<td align="center">352 (7.6%)</td>
<td align="center">0.79 (0.68-0.93)</td>
<td align="center">0.004</td>
</tr>
</tbody>
</table>
<p>Among patients not on dialysis at baseline, VYTORIN did not reduce the risk of progressing to end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> compared with placebo (RR 0.97: 95% CI 0.89-1.05).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_cef7a992-7340-4287-8996-0bf6a10e63d5"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">No. 3873 — Tablets VYTORIN 10/10 are white to off-white capsule-shaped tablets with code "311" on one side.</p>
<p>They are supplied as follows: </p>
<a name="ieda2a664-4ad2-49fa-8525-4df8e9a24fa6"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5250-0<br>
</td>
</tr></tbody></table>
<p>No. 3874 — Tablets VYTORIN 10/20 are white to off-white capsule-shaped tablets with code "312" on one side.</p>
<p>They are supplied as follows: </p>
<a name="i5e3d1f80-cb17-4575-8fe4-a65abb47f2ba"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 15<br>
</td>
<td>NDC 54868-5187-2<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5187-0<br>
</td>
</tr>
</tbody></table>
<p>No. 3875 — Tablets VYTORIN 10/40 are white to off-white capsule-shaped tablets with code "313" on one side.</p>
<p>They are supplied as follows: </p>
<a name="ia6924ead-d207-4e26-85b7-63bd8f54c93b"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5189-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 90<br>
</td>
<td>NDC 54868-5189-1<br>
</td>
</tr>
</tbody></table>
<p>No. 3876 — Tablets VYTORIN 10/80 are white to off-white capsule-shaped tablets with code "315" on one side.</p>
<p>They are supplied as follows: </p>
<a name="i024c81ac-5cf9-4c27-81e2-c857c1fbebe9"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5259-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 90<br>
</td>
<td>NDC 54868-5259-1<br>
</td>
</tr>
</tbody></table>
<p><span class="Italics"><span class="Bold">Storage</span></span></p>
<p>Store at 20-25°C (68-77°F). [See USP Controlled Room Temperature.] Keep container tightly closed.</p>
<p><span class="Italics"><span class="Bold"><br></span></span></p>
<br>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_66cb556c-ff55-4f85-ba8b-05b269442467"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"> See <a href="#i4i_patient_package_insert_id_5e1e2c90-36e1-48bb-b0d4-169acbde2c10">FDA-Approved Patient Labeling (Patient Information)</a>. </p>
<p>Patients should be advised to adhere to their National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program (NCEP)-recommended diet, a regular exercise program, and periodic testing of a fasting lipid panel.</p>
<p><span class="Bold">Patients should be advised about substances they should not take concomitantly with VYTORIN <span class="Italics"> [see <span class="Italics"><a href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">Contraindications (4) </a></span>and <span class="Italics"><a href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">Warnings and Precautions (5.1)</a></span>]. </span>Patients should also be advised to inform other healthcare professionals prescribing a new medication or increasing the dose of an existing medication that they are taking VYTORIN.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b642cbb9-73a8-439d-8fbf-87f65bb6da3f"></a><a name="section-15.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span></h2>
<p class="First">All patients starting therapy with VYTORIN should be advised of the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and told to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. <span class="Bold">Patients using the 10/80-mg dose should be informed that the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, is increased with the use of the 10/80-mg dose.</span> The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, occurring with use of VYTORIN is increased when taking certain types of medication or consuming larger quantities of grapefruit juice. Patients should discuss all medication, both prescription and over the counter, with their healthcare professional.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60860178-ce1a-439d-a924-4cfc6af75909"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Liver Enzymes</h2>
<p class="First">It is recommended that liver function tests be performed before the initiation of VYTORIN, and thereafter when clinically indicated. All patients treated with VYTORIN should be advised to report promptly any symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_61eaf884-d508-4b2f-8c5a-78bb46771af3"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Pregnancy</h2>
<p class="First">Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using VYTORIN. Discuss future pregnancy plans with your patients, and discuss when to stop taking VYTORIN if they are trying to conceive. Patients should be advised that if they become pregnant they should stop taking VYTORIN and call their healthcare professional.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_767a54ce-7ee4-4c9e-a807-53a2d3747ff4"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Breast-feeding</h2>
<p class="First">Women who are breast-feeding should be advised to not use VYTORIN. Patients who have a lipid disorder and are breast-feeding should be advised to discuss the options with their healthcare professional.<br><br></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured for: MSP Distribution Services (C) LLC, a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>By:<br>MSD International GmbH (Singapore Branch)<br>Singapore 637766</p>
<p>Or</p>
<p>Merck Sharp &amp; Dohme (Italia) S.p.A.<br>Via Emilia, 21<br>27100 – Pavia, Italy</p>
<p>Or</p>
<p>Merck Sharp &amp; Dohme Ltd.<br>Cramlington, Northumberland, UK NE23 3JU</p>
<p>Or</p>
<p>Jointly manufactured by:<br>Merck Sharp &amp; Dohme (Italia) S.p.A.<br>Via Emilia, 21<br>27100 – Pavia, Italy<br>and<br>MSD International GmbH (Singapore Branch)<br>Singapore 637766</p>
<p>U.S. Patent Nos. 5,846,966 and RE42,461</p>
<p>Revised: 02/2012</p>
<p>9619523<br><br><br></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">Distributed and Repackaged by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma       74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_5e1e2c90-36e1-48bb-b0d4-169acbde2c10"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">VYTORIN<span class="Sup">®</span> (ezetimibe/simvastatin) Tablets<br>Patient Information about VYTORIN (VI-tor-in)</span><br>Generic name: ezetimibe/simvastatin tablets</p>
<p>Read this information carefully before you start taking VYTORIN<span class="Sup">®</span>. Review this information each time you refill your prescription for VYTORIN as there may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about VYTORIN, ask your doctor. Only your doctor can determine if VYTORIN is right for you.</p>
<p><span class="Bold">What is VYTORIN?</span></p>
<p>VYTORIN contains two <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering medications, ezetimibe and simvastatin. VYTORIN is a prescription medicine used to lower levels of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL (bad) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and fatty substances called triglycerides in the blood. In addition, VYTORIN raises levels of HDL (good) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. VYTORIN is for patients who cannot control their <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels by diet and exercise alone. You should stay on a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering diet while taking this medicine. </p>
<p>VYTORIN works to reduce your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in two ways. It reduces the <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorbed in your digestive tract, as well as the <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> your body makes by itself. VYTORIN does not help you lose weight. </p>
<p>VYTORIN has not been shown to reduce <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> more than simvastatin alone.</p>
<p>The usual dose of VYTORIN is 10/10 mg to 10/40 mg 1 time each day.</p>
<p>VYTORIN 10/80 mg increases your chance of developing <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span>. The 10/80 mg dose should only be used by people who:</p>
<ul>
<li>have been taking VYTORIN 10/80 mg chronically (such as 12 months or more) without having <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span> </li>
<li>do not need to take certain other medicines with VYTORIN that would increase your chance of getting <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span>.</li>
</ul>
<p>If you are unable to reach your LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> goal using VYTORIN 10/40 mg, your doctor should switch you to another <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering medicine.</p>
<p>For more information about <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, see the section called "What should I know about high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>?"</p>
<p><span class="Bold">Who should not take VYTORIN?</span></p>
<p><span class="Bold">Do not take VYTORIN if you take:</span></p>
<ul>
<li>Certain anti-fungal medicines including: <ul>
<li>itraconazole</li>
<li>ketoconazole</li>
<li>posaconazole</li>
</ul>
</li>
<li>HIV protease inhibitors (indinavir, nelfinavir, ritonavir, saquinavir, tipranavir, or atazanavir)</li>
<li>Certain <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus protease inhibitors (such as boceprevir or telaprevir)</li>
<li>Certain antibiotics, including: <ul>
<li>erythromycin</li>
<li>clarithromycin</li>
<li>telithromycin</li>
</ul>
</li>
<li>nefazodone</li>
<li>A fibric acid medicine for lowering <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> called gemfibrozil</li>
<li>cyclosporine</li>
<li>danazol</li>
</ul>
<p>Ask your doctor if you are not sure if your medicine is listed above. </p>
<p><span class="Bold">Also do not take VYTORIN:</span></p>
<ul>
<li>If you are allergic to ezetimibe or simvastatin, the active ingredients in VYTORIN, or to the inactive ingredients. For a list of inactive ingredients, see the "Inactive ingredients" section at the end of this information sheet.<br><br>
</li>
<li>If you have active liver disease or repeated blood tests indicating possible liver problems.<br><br>
</li>
<li>If you are pregnant, or think you may be pregnant, or planning to become pregnant or breast-feeding.<br><br>
</li>
<li>If you are a woman of childbearing age, you should use an effective method of birth control to prevent pregnancy while using VYTORIN.</li>
</ul>
<p>VYTORIN has not been studied in children under 10 years of age.</p>
<p><span class="Bold">What should I tell my doctor before and while taking VYTORIN?</span></p>
<p><span class="Bold">Tell your doctor right away if you have unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> while you take VYTORIN. Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<p>The risk of muscle breakdown is greater at higher doses of VYTORIN, particularly the 10/80 mg dose.</p>
<p>The risk of muscle breakdown is greater in people 65 years of age and older, females, and people with kidney or thyroid problems.</p>
<p>Taking VYTORIN with certain substances can increase the risk of muscle problems. It is especially important to tell your doctor if you take:</p>
<ul>
<li>fibric acid derivatives (such as fenofibrate)</li>
<li>amiodarone (a drug used to treat an irregular heartbeat)</li>
<li>verapamil, diltiazem, amlodipine, or ranolazine (drugs used to treat high blood pressure, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> associated with heart disease, or other heart conditions)</li>
<li>large quantities of grapefruit juice (more than 1 quart daily)</li>
<li>colchicine (a medicine used to treat <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>)</li>
<li>voriconazole (an anti-fungal medicine)</li>
<li>large doses of niacin or nicotinic acid</li>
</ul>
<p>Tell your doctor if you are taking niacin or a niacin-containing product, as this may increase your risk of muscle problems, especially if you are Chinese.</p>
<p>It is also important to tell your doctor if you are taking coumarin anticoagulants (drugs that prevent blood clots, such as warfarin).</p>
<p>Tell your doctor about all the medicines you take, including any prescription and nonprescription medicines, vitamins, and herbal supplements.</p>
<p>If you have more than 1 doctor, tell all of your doctors that you take VYTORIN. This is especially important when they prescribe a new medicine or increase the dose of your other medicines. </p>
<p>Tell your doctor about all your medical conditions including allergies.</p>
<p>Tell your doctor if you:<br><br></p>
<ul>
<li>drink substantial quantities of alcohol or ever had liver problems. VYTORIN may not be right for you. <br><br>
</li>
<li>are pregnant or plan to become pregnant. Do not use VYTORIN if you are pregnant, trying to become pregnant or suspect that you are pregnant. If you become pregnant while taking VYTORIN, stop taking it and contact your doctor immediately.<br><br>
</li>
<li>are breast-feeding. Do not use VYTORIN if you are breast-feeding.</li>
</ul>
<p>Tell other doctors prescribing a new medication that you are taking VYTORIN.</p>
<p><span class="Bold">How should I take VYTORIN?</span></p>
<br><ul>
<li>Take VYTORIN exactly as your doctor tells you to take it.<br><br>
</li>
<li>Take VYTORIN once a day, in the evening, with or without food. <br><br>
</li>
<li>If you miss a dose, do not take an extra dose. Just resume your usual schedule.<br><br>
</li>
<li>Continue to follow a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering diet while taking VYTORIN. Ask your doctor if you need diet information.<br><br>
</li>
<li>Keep taking VYTORIN unless your doctor tells you to stop. If you stop taking VYTORIN, your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> may rise again.</li>
</ul>
<p><span class="Bold">What should I do in case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>?</span></p>
<p>Contact your doctor immediately.</p>
<p><span class="Bold">What are the possible side effects of VYTORIN?</span></p>
<p>See your doctor regularly to check your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> level and to check for side effects. Your doctor should do blood tests to check your liver before you start taking VYTORIN and if you have any symptoms of liver problems while you take VYTORIN. Call your doctor right away if you have the following symptoms of liver problems:</p>
<ul>
<li>feel tired or weak</li>
<li>loss of appetite</li>
<li>upper belly <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>dark urine</li>
<li>yellowing of your skin or the whites of your eyes</li>
</ul>
<p>In clinical studies patients reported the following common side effects while taking VYTORIN: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (see What should I tell my doctor before and while taking VYTORIN?).</p>
<p>The following side effects have been reported in general use with VYTORIN or with ezetimibe or simvastatin tablets (tablets that contain the active ingredients of VYTORIN):</p>
<ul><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing (which may require treatment right away), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>; raised red <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sometimes with target-shaped lesions; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>; alterations in some laboratory blood tests; liver problems (sometimes serious); <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling sensation</span>; <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>; <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the gallbladder; trouble sleeping; poor memory; <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>; breathing problems including persistent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and/or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</li></ul>
<p>Tell your doctor if you are having these or any other medical problems while on VYTORIN. This is <span class="Underline">not</span> a complete list of side effects. For a complete list, ask your doctor or pharmacist.</p>
<p><span class="Bold">What should I know about high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>?</span></p>
<p><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> is a type of fat found in your blood. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> comes from two sources. It is produced by your body and it comes from the food you eat. Your total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is made up of both LDL and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. </p>
<p>LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is called "bad" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> because it can build up in the wall of your arteries and form plaque. Over time, plaque build-up can cause a narrowing of the arteries. This narrowing can slow or block blood flow to your heart, brain, and other organs. High LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is a major cause of heart disease and one of the causes for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p>HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is called "good" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> because it keeps the bad <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> from building up in the arteries. </p>
<p>Triglycerides also are fats found in your body.</p>
<p><span class="Bold">General Information about VYTORIN</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use VYTORIN for a condition for which it was not prescribed. Do not give VYTORIN to other people, even if they have the same condition you have. It may harm them. </p>
<p>This summarizes the most important information about VYTORIN. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about VYTORIN that is written for health professionals. For additional information, visit the following web site: vytorin.com.</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<p>Butylated hydroxyanisole NF, citric acid monohydrate USP, croscarmellose sodium NF, hypromellose USP, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, and propyl gallate NF.<br><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<p class="First">Manufactured for: MSP Distribution Services (C) LLC, a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>This patient information has been approved by the U.S. Food and Drug Administration</p>
<p>Revised: 02/2012</p>
<p>9619523</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_cba05681-9144-453d-b0fe-6f86f6d1d74b"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Bottle Label 10/10</span></p>
<p><span class="Italics"><span class="Bold">VYTORIN<span class="Sub">®</span> 10/10</span><br>(ezetimibe/simvastatin)</span></p>
<p></p>
<p>Each tablet contains 10 mg ezetimibe and <br>10 mg simvastatin.</p>
<p>Store at 20-25°C (68-77°F). <br>[See USP Controlled Room Temperature.]<br>Keep container tightly closed.</p>
<p></p>
<p><span class="Bold">Rx only</span></p>
<p>USUAL ADULT DOSAGE: <br>See accompanying circular.</p>
<p></p>
<p></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Bottle Label 10/10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2507c644-e445-4e31-8d15-82afcb15f274&amp;name=5250.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d8a0862d-b2e4-465b-9906-85cb67eb7bfb"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Bottle Label 10/20</span></p>
<p><span class="Italics"><span class="Bold">VYTORIN<span class="Sub">®</span> 10/20</span><br>(ezetimibe/simvastatin)</span></p>
<p></p>
<p>Each tablet contains 10 mg ezetimibe and <br>20 mg simvastatin.</p>
<p>Store at 20-25°C (68-77°F). <br>[See USP Controlled Room Temperature.]<br>Keep container tightly closed.</p>
<p></p>
<p><span class="Bold">Rx only</span></p>
<p>USUAL ADULT DOSAGE: <br>See accompanying circular.</p>
<p></p>
<p></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Bottle Label 10/20" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2507c644-e445-4e31-8d15-82afcb15f274&amp;name=5187.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_46c40b11-c67a-4f38-b505-0956ad73b185"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Bottle Label 10/40</span></p>
<p><span class="Italics"><span class="Bold">VYTORIN<span class="Sub">®</span> 10/40</span><br>(ezetimibe/simvastatin)</span></p>
<p></p>
<p>Each tablet contains 10 mg ezetimibe and <br>40 mg simvastatin.</p>
<p>Store at 20-25°C (68-77°F). <br>[See USP Controlled Room Temperature.]<br>Keep container tightly closed.</p>
<p></p>
<p><span class="Bold">Rx only</span></p>
<p>USUAL ADULT DOSAGE: <br>See accompanying circular.</p>
<p></p>
<p></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Bottle Label 10/40" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2507c644-e445-4e31-8d15-82afcb15f274&amp;name=5189.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2243eea5-95e6-4ab1-832e-c88a2d83fc5b"></a><a name="section-22"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Bottle Label 10/80</span></p>
<p><span class="Italics"><span class="Bold">VYTORIN<span class="Sub">®</span> 10/80</span><br>(ezetimibe/simvastatin)</span></p>
<p></p>
<p>Each tablet contains 10 mg ezetimibe and <br>80 mg simvastatin.</p>
<p>Store at 20-25°C (68-77°F). <br>[See USP Controlled Room Temperature.]<br>Keep container tightly closed.</p>
<p></p>
<p><span class="Bold">Rx only</span></p>
<p>USUAL ADULT DOSAGE: <br>See accompanying circular.</p>
<p></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Bottle Label 10/80" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2507c644-e445-4e31-8d15-82afcb15f274&amp;name=5259.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VYTORIN 		
					</strong><br><span class="contentTableReg">ezetimibe and simvastatin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5250(NDC:66582-311)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ezetimibe</strong> (ezetimibe) </td>
<td class="formItem">ezetimibe</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>simvastatin</strong> (simvastatin) </td>
<td class="formItem">simvastatin</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butylated hydroxyanisole</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propyl gallate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">311</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5250-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021687</td>
<td class="formItem">03/14/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VYTORIN 		
					</strong><br><span class="contentTableReg">ezetimibe and simvastatin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5187(NDC:66582-312)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ezetimibe</strong> (ezetimibe) </td>
<td class="formItem">ezetimibe</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>simvastatin</strong> (simvastatin) </td>
<td class="formItem">simvastatin</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butylated hydroxyanisole</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propyl gallate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">312</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5187-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5187-2</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021687</td>
<td class="formItem">11/19/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VYTORIN 		
					</strong><br><span class="contentTableReg">ezetimibe and simvastatin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5189(NDC:66582-313)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ezetimibe</strong> (ezetimibe) </td>
<td class="formItem">ezetimibe</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>simvastatin</strong> (simvastatin) </td>
<td class="formItem">simvastatin</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butylated hydroxyanisole</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propyl gallate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">313</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5189-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5189-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021687</td>
<td class="formItem">11/19/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VYTORIN 		
					</strong><br><span class="contentTableReg">ezetimibe and simvastatin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5259(NDC:66582-315)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ezetimibe</strong> (ezetimibe) </td>
<td class="formItem">ezetimibe</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>simvastatin</strong> (simvastatin) </td>
<td class="formItem">simvastatin</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butylated hydroxyanisole</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propyl gallate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">315</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5259-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5259-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021687</td>
<td class="formItem">04/04/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-5259, 54868-5189, 54868-5187, 54868-5250), repack(54868-5259, 54868-5189, 54868-5187, 54868-5250)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>03da19ea-d024-469b-a606-892170bb9ccd</div>
<div>Set id: 2507c644-e445-4e31-8d15-82afcb15f274</div>
<div>Version: 2</div>
<div>Effective Time: 20120906</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
